UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

 ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2021

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

 

For the transition period from

 

__________ to __________

  

Commission file number 000-49877

 

ON TRACK INNOVATIONS LTD.
(Exact name of registrant as specified in its charter)

 

Israel   N/A
(State or other jurisdiction of incorporation or organization)   (IRS Employer Identification No.)

 

Hatnufa 5, Yokneam Industrial Zone
Box 372, Yokneam, Israel  
  2069200
(Address of principal executive offices)     (Zip Code)

 

Registrant’s telephone number, including area code: + 972-4-6868000

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
None        

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    

 

Yes ☒    No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    

 

Yes ☒    No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐

Non-accelerated filer ☒

Smaller reporting company ☒  

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ☐    No ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date: 72,789,893 Ordinary Shares outstanding as of August 9, 2021.

 

 

 

 

 

 

ON TRACK INNOVATIONS LTD.

 

TABLE OF CONTENTS

 

Part I - Financial Information    
         
Item 1.   Financial Statements   1
         
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations   2
         
Item 4.   Controls and Procedures   12
         
Part II - Other Information    
         
Item 1.   Legal Proceedings   13
         
Item 1A.   Risk Factors   13
         
Item 5   Other Information   13
         
Item 6.   Exhibits   16
         
    Signatures   17

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Item 1.   Financial Statements.

 

ON TRACK INNOVATIONS LTD. AND ITS SUBSIDIARIES

 

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

As of June 30, 2021

 

(Unaudited)

 

1

 

 

 

 

 

 

 

 

 

 

 

On Track Innovations Ltd.

and its Subsidiaries

 

Interim Condensed Consolidated

Financial Statements

As of June 30, 2021

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

On Track Innovations Ltd.

and its Subsidiaries

 

Interim Unaudited Condensed Consolidated Financial Statements as of June 30, 2021

 

Contents   Page
     
Interim Unaudited Condensed Consolidated Balance Sheets   F-2 - F-3
     
Interim Unaudited Condensed Consolidated Statements of Operations   F-4
     
Interim Unaudited Condensed Consolidated Statements of Comprehensive Loss   F-5
     
Interim Unaudited Condensed Consolidated Statements of Changes in Equity   F-6 - F-7
     
Interim Unaudited Condensed Consolidated Statements of Cash Flows   F-8 - F-9
     
Notes to the Interim Unaudited Condensed Consolidated Financial Statements   F-10 - F-33

  

F-1

 

 

On Track Innovations Ltd.

and its Subsidiaries

 

Interim Unaudited Condensed Consolidated Balance Sheets

 

US dollars in thousands except share data

 

    June 30,     December 31,  
    2021     2020  
Assets            
             
Current assets            
Cash and cash equivalents   $ 959     $ 1,377  
Short-term investments     1,605       105  
Trade receivables (net of allowance for doubtful accounts of $609 and $620 as of June 30, 2021 and December 31, 2020, respectively)     2,139       1,148  
Other receivables and prepaid expenses     2,712       695  
Inventories     2,742       2,479  
Assets from discontinued operations - held for sale     -       6,358  
                 
Total current assets     10,157       12,162  
                 
Non-current assets                
                 
Long term restricted deposit for employee benefits     504       511  
                 
Severance pay deposits     406       411  
                 
Property, plant and equipment, net     705       752  
                 
Intangible assets, net     189       247  
                 
Right-of-use assets due to operating leases     2,508       2,903  
                 
Total non-current assets     4,312       4,824  
                 
Total Assets   $ 14,469     $ 16,986  

 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

 

F-2

 

 

On Track Innovations Ltd.

and its Subsidiaries

 

Interim Unaudited Condensed Consolidated Balance Sheets

 

US dollars in thousands except share data

 

    June 30,     December 31,  
    2021     2020  
Liabilities and Equity            
             
Current Liabilities            
Short-term bank credit, short-term loans and current maturities of long-term bank loans   $ 795     $ 542  
Convertible short-term loan from a controlling shareholder     77       625  
Trade payables     2,212       1,667  
Other current liabilities     4,270       2,283  
Liabilities from discontinued operations - held for sale    
-
      5,829  
                 
Total current liabilities   $ 7,354     $ 10,946  
                 
Long-Term Liabilities                
Long-term loans, net of current maturities     8       14  
Long-term liabilities due to operating leases, net of current maturities     1,931       2,343  
Accrued severance pay     977       977  
Total long-term liabilities     2,916       3,334  
                 
Total Liabilities     10,270       14,280  
                 
Commitments and Contingencies, see Note 6    
 
     
 
 
                 
Equity                
                 
Ordinary shares of NIS 0.1 par value: Authorized – 100,000,000 shares as of June 30, 2021 and December 31, 2020; issued: 73,968,592 and 55,003,076 shares as  of June 30, 2021 and December 31, 2020, respectively; outstanding: 72,789,893 and 53,824,377 shares  as of June 30, 2021 and December 31, 2020, respectively     2,008       1,423  
Additional paid-in capital     233,391       227,209  
Treasury shares at cost - 1,178,699 shares as of June 30, 2021 and December 31, 2020     (2,000 )     (2,000 )
Accumulated other comprehensive loss     (352 )     (961 )
Accumulated deficit     (228,848 )     (222,965 )
Total Equity     4,199       2,706  
                 
Total Liabilities and Equity   $ 14,469     $ 16,986  

 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

 

F-3

 

 

On Track Innovations Ltd.

and its Subsidiaries

 

Interim Unaudited Condensed Consolidated Statements of Operations

 

US dollars in thousands except share and per share data

 

    Three months ended June 30,     Six months ended June 30,  
    2021     (*)2020     2021     (*)2020  
Revenues                        
Sales   $ 2,446     $ 3,751     $ 4,833     $ 7,094  
Software as a Service (“SaaS”)     405       286       787       610  
                                 
Total revenues     2,851       4,037       5,620       7,704  
                                 
Cost of revenues                                
Cost of sales     1,874       2,358       3,240       4,379  
Total cost of revenues     1,874       2,358       3,240       4,379  
                                 
Gross profit     977       1,679       2,380       3,325  
Operating expenses                                
Research and development     900       903       1,738       1,796  
Selling and marketing     736       885       1,341       1,583  
General and administrative     735       698       1,481       1,500  
Total operating expenses     2,371       2,486       4,560       4,879  
                                 
Operating loss from continuing operations     (1,394 )     (807 )     (2,180 )     (1,554 )
Loss from change in fair value of embedded derivative    
-
     
-
      (1,974 )    
-
 
Other financial (expenses) income, net     (131 )     (109 )     (127 )     67  
Financial (expenses) income, net     (131 )     (109 )     (2,101 )     67  
Loss from continuing operations before taxes on income     (1,525 )     (916 )     (4,281 )     (1,487 )
Income tax benefits (expenses)    
-
      (12 )     13       (17 )
Loss from continuing operations     (1,525 )     (928 )     (4,268 )     (1,504 )
Loss from discontinued operations     (1,197 )     (195 )     (1,615 )     (288 )
Net loss   $ (2,722 )   $ (1,123 )   $ (5,883 )   $ (1,792 )
                                 
Basic and diluted net loss attributable to shareholders per ordinary share (***)                                
From continuing operations     (0.02 )     (0.02 )     (0.07 )     (0.03 )
From discontinued operations     (0.02 )    
(**)
      (0.03 )     (0.01 )
                                 
    $ (0.04 )   $ (0.02 )   $ (0.10 )   $ (0.04 )
                                 
Weighted average number of ordinary shares used in computing basic and diluted net loss per ordinary share     62,577,692      
(***)56,335,759
      58,225,215      
(***)53,840,138
 

 

(*) Reclassified to conform with the current period presentation, see Note 1C(2).
(**) Less than $0.01 per ordinary share.
(***)

Basic and diluted net losses attributable to shareholders per ordinary share for previous reporting periods were retroactively adjusted due to the completion of rights offering, see Note 1E.

 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

 

F-4

 

 

On Track Innovations Ltd.

and its Subsidiaries

 

Interim Unaudited Condensed Consolidated Statements of Comprehensive Loss

 

US dollars in thousands

 

    Three months ended June 30,     Six months ended June 30,  
    2021     (*)2020     2021     (*)2020  
Total comprehensive loss:                        
Net loss   $ (2,722 )   $ (1,123 )   $ (5,883 )   $ (1,792 )
Exchange differences on translation released following sale of a subsidiary     746      
-
      746      
-
 
Exchange differences on translation of foreign continuing operations    
-
      (49 )     (85 )     (31 )
Exchange differences on translation of foreign discontinued operations    
-
      190       (52 )     (122 )
                                 
Total comprehensive loss   $ (1,976 )   $ (982 )   $ (5,274 )   $ (1,945 )

 

(*) Reclassified to conform with the current period presentation, see Note 1C(2).

 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

 

F-5

 

 

On Track Innovations Ltd.

and its Subsidiaries

 

Interim Unaudited Condensed Consolidated Statements of Changes in Equity

 

US dollars in thousands except for number of shares

 

    Number of Shares issued     Share capital     Additional paid-in capital     Treasury Shares (at cost)     Accumulated other comprehensive Income (loss)     Accumulated deficit     Total equity  
Balance as of March 31, 2020     49,003,076     $ 1,256     $ 226,152     $ (2,000 )   $ (1,268 )   $ (217,501 )   $ 6,639  
                                                         
Changes during the three months period ended June 30, 2020:                                                        
                                                         
Issuance of shares, net of issuance costs of $31 (*)     6,000,000       167       1,002      
-
     
-
     
-
      1,169  
Stock-based compensation     -      
-
      16      
-
     
-
     
-
      16  
Exchange differences on translation adjustments     -      
-
     
-
     
-
      141      
-
      141  
Net loss     -      
-
     
-
     
-
     
-
      (1,123 )     (1,123 )
Balance as of June 30, 2020     55,003,076     $ 1,423     $ 227,170     $ (2,000 )   $ (1,127 )   $ (218,624 )   $ 6,842  
                                                         
Balance as of March 31, 2021     55,003,076     $ 1,423     $ 230,789     $ (2,000 )   $ (1,098 )   $ (226,126 )   $ 2,988  
                                                         
Changes during the three months period ended June 30, 2021:                                                        
                                                         
Issuance of shares, net of issuance costs of $128 (*)     18,965,516       585       2,587      
-
     
-
     
-
      3,172  
Stock-based compensation     -      
-
      15      
-
     
-
     
-
      15  
Exchange differences on translation released following sale of a subsidiary     -      
-
     
-
     
-
      746      
-
      746  
Net loss     -      
-
     
-
     
-
     
-
      (2,722 )     (2,722 )
Balance as of June 30, 2021     73,968,592     $ 2,008     $ 233,391     $ (2,000 )   $ (352 )   $ (228,848 )   $ 4,199  

 

(*) See Note 10A.

 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

 

F-6

 

 

On Track Innovations Ltd.

and its Subsidiaries

 

Interim Unaudited Condensed Consolidated Statements of Changes in Equity

 

US dollars in thousands except for number of shares

 

    Number of Shares issued     Share capital     Additional paid-in capital     Treasury Shares (at cost)     Accumulated other comprehensive Income (loss)     Accumulated deficit     Total equity  
Balance as of December 31, 2019     47,963,076     $ 1,226     $ 225,970     $ (2,000 )   $ (974 )   $ (216,832 )   $ 7,390  
                                                         
Changes during the six months period ended June 30, 2020:                                                        
                                                         
Issuance of shares, net of issuance costs of $39 (*)     7,040,000       197       1,172      
-
     
-
     
-
      1,369  
Stock-based compensation     -      
-
      28      
-
     
-
     
-
      28  
Exchange differences on translation adjustments     -      
-
     
-
     
-
      (153 )    
-
      (153 )
Net loss     -      
-
     
-
     
-
     
-
      (1,792 )     (1,792 )
Balance as of June 30, 2020     55,003,076     $ 1,423     $ 227,170     $ (2,000 )   $ (1,127 )   $ (218,624 )   $ 6,842  
                                                         
Balance as of December  31, 2020     55,003,076     $ 1,423     $ 227,209     $ (2,000 )   $ (961 )   $ (222,965 )   $ 2,706  
                                                         
Changes during the six months period ended June 30, 2021:                                                        
                                                         
Issuance of shares, net of issuance costs of $128 (*)     18,965,516       585       2,587      
-
     
-
     
-
      3,172  
Stock-based compensation     -      
-
      29      
-
     
-
     
-
      29  
Exchange differences on translation adjustments     -      
-
     
-
     
-
     
(**)609
   
-
      609  
Classification of embedded derivative from liability to equity (***)    
-
     
-
      3,566      
-
     
-
     
-
      3,566  
Net loss     -      
-
     
-
     
-
     
-
      (5,883 )     (5,883 )
Balance as of June 30, 2021     73,968,592     $ 2,008     $ 233,391     $ (2,000 )   $ (352 )   $ (228,848 )   $ 4,199  

 

(*) See Note 10A.
(**) Including exchange differences on translation released following sale of a subsidiary in amount of $746.
(***) See Note 5.

  

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

 

F-7

 

 

On Track Innovations Ltd.

and its Subsidiaries

 

Interim Unaudited Condensed Consolidated Statements of Cash Flows

 

US dollars in thousands

 

    Six months ended June 30,  
    2021     (*) 2020  
Cash flows from continuing operating activities            
Net loss from continuing operations   $ (4,268 )   $ (1,504 )
Adjustments required to reconcile net loss to net cash used in provided by continuing operating activities:                
Stock-based compensation related to options issued to employees and others     29       28  
Accrued interest and linkage differences, net     (55 )     (162 )
Transaction expenses related to convertible short-term loan received from shareholders     10      
-
 
Loss from change in fair value of embedded derivative     1,974      
-
 
Depreciation and amortization     200       212  
Deferred tax (benefits) expenses, net     (13 )     17  
                 
Changes in operating assets and liabilities:                
Change in accrued severance pay, net     5       11  
(Increase) decrease in trade receivables, net     (1,143 )     92  
Increase in other receivables and prepaid expenses     (416 )     (92 )
(Increase) decrease in inventories     (263 )     380  
Increase in trade payables     544       1,268  
Increase (decrease) in other current liabilities     173       (283 )
Net cash used in continuing operating activities     (3,223 )     (33 )
                 
Cash flows from continuing investing activities                
Purchase of property and equipment and intangible assets     (137 )     (283 )
Change in short-term investments, net     (1,500 )     511  
Net cash (used in) provided by continuing investing activities     (1,637 )     228  
                 
Cash flows from continuing financing activities                
(Decrease) increase in short-term bank credit and loans, net     (1,474 )     62  
Convertible short-term loan received from shareholders, net of transaction expenses     923      
-
 
Repayment of long-term bank loans     (2 )     (7 )
Proceeds from issuance of shares, net of issuance costs     3.209       1,369  
Net cash provided by continuing financing activities     2,656       1,424  
                 
Cash flows from discontinued operations                
Net cash used in discontinued operating activities     (91 )     (1,300 )
Net cash provided by (used in) discontinued investing activities     1,338       (207 )
Net cash (used in) provided by discontinued financing activities     (380 )     799  
                 
Total net cash provided by (used in) discontinued operations     867       (708 )
                 
Effect of exchange rate changes on cash and cash equivalents     (98 )     (86 )
                 
(Decrease) increase in cash, cash equivalents and restricted cash     (1,435 )     825  
Cash, cash equivalents and restricted cash - beginning of the period    
(**)2,499
     
(**)2,648
 
                 
Cash, cash equivalents and restricted cash - end of the period   $ 1,064     $
(**)3,473
 

 

(*) Reclassified to conform with the current period presentation, see Note 1C(2).
(**) Including cash and cash equivalents from discontinued operations held for sale. See also Note 8.

 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

 

F-8

 

 

On Track Innovations Ltd.

and its Subsidiaries

 

Interim Unaudited Condensed Consolidated Statements of Cash Flows

 

US dollars in thousands

 

    Six months ended June 30  
    2021     2020  
Supplementary cash flows activities:                
                 
Cash paid during the period for:                
                 
Interest paid   $
(*)55
    $ 51  
                 
Income taxes paid   $ -     $
(**)40
 
                 
Income tax refund received   $ 6     $
-
 

 

(*) Including $7 that derives from discontinued operations.

(**) Derives from discontinued operations.

 

Supplemental disclosures of non-cash flow information            
Payables due to issuance costs   $ 37     $
-
 
Payables due to purchase of property and equipment and intangible assets   $ -     $ 12  
Payables due to purchase of property and equipment and intangible assets from discontinued operations - held for sale   $
-
    $
(*)75
 
Classification of embedded derivative from liability to equity   $ 3,566     $
-
 

 

(*) Derives from discontinued operations

 

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

 

F-9

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 1 - Organization and Basis of Presentation

 

A. Description of business

 

On Track Innovations Ltd. (the “Company”) was founded in 1990, in Israel. The Company and its subsidiaries (together, the “Group”) are principally engaged in the field of design and development of cashless payment solutions.

 

The Company’s ordinary shares are quoted for trading on the OTCQX market (formerly listed on the Nasdaq Capital Market until October 31, 2019).

 

As of June 30, 2021, the Company operates in two operating segments: (a) Retail, and (b) Petroleum (see Note 11). The Company completed the sale of its Mass Transit Ticketing operation in April 2021 (see Note 1C(2)). The Company has determined that the Mass Transit Ticketing business qualifies as a discontinued operation. Accordingly, the results and the cash flows of this operation for all reporting periods are presented in the statements of operations and in the statements of cash flows, respectively, as discontinued operations separately from continuing operations. In addition, the sale of the Mass Transit Ticketing business qualified as held for sale as of December 31, 2020.

 

B. Interim Unaudited Financial Information

 

The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and therefore should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

 

In the opinion of management, all adjustments considered necessary for a fair statement, consisting of normal recurring adjustments, have been included. Operating results for the six-month period and the three-month period ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021.

 

Use of Estimates:

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the assets, liabilities, revenue, costs, expenses and accumulated other comprehensive loss that are reported in the Interim Consolidated Financial Statements and accompanying disclosures. These estimates are based on management’s best knowledge of current events, historical experience, actions that the Company may undertake in the future and on various other assumptions that are believed to be reasonable under the circumstances. As a result, actual results may be different from these estimates.

 

F-10

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 1 - Organization and Basis of Presentation (cont’d)

 

C. Divestiture of operations

 

1. In December 2013, the Company completed the sale of certain assets, subsidiaries and intellectual property relating to its Smart ID division, for a total purchase price of $10,000 in cash and an additional $12,500 subject to performance-based milestones. Accordingly, the results and the cash flows of this operation for all reporting periods are presented in the statements of operations and in the statements of cash flows, respectively, as discontinued operations separately from continuing operations.

 

On April 20, 2016, the purchaser of the Smart ID division, SuperCom Ltd. (“SuperCom”), and the Company entered into a settlement agreement resolving certain litigation between SuperCom and the Company pursuant to which SuperCom paid the Company $2,050 and agreed to pay the Company up to $1,500 in accordance with and subject to a certain earn-out mechanism. In November 2017, the Company commenced an arbitration procedure with SuperCom, in which the Company claims that additional earn-out payments have not been paid to the Company. SuperCom raised claims against the Company during the arbitration for material damages. An arbitration decision was issued on December 24, 2018 in the Company’s favor and denied SuperCom’s claims. The arbitrator ordered SuperCom to disclose the financial information regarding the earn-out payments that the Company is entitled to receive, and to pay the Company accordingly, or otherwise pay the Company approximately $1,300 that reflects the maximum earn-out amount that has not yet been paid to the Company by SuperCom. The arbitration verdict was approved as a court’s verdict in June 2019, but SuperCom failed to disclose the financial information in the way it should have done according to the arbitration decision. Therefore, in December 2019 the Company submitted a complementary claim to the arbitrator, asking for a final award that includes a final payment by SuperCom (as opposed to merely disclosing information). On January 21, 2021, after conclusion of the evidence phase in the arbitration, and after the Company already filed its summaries, SuperCom submitted new documents claiming that these include the missing financial information. Following the submission of these documents, on February 9, 2021, the Company submitted an application claiming that implementing the contractual sanction mechanism on the amounts presented in these documents testifies to the Company’s entitlement to the maximum earn-out amount, and, therefore, the arbitrator is requested to order that the parties will complete their summaries and then a verdict will be given. On March 8, 2021, the arbitrator accepted the Company’s application and on April 11, 2021, the Company submitted complementary summaries. Following an arbitration process between the Company and SuperCom, on August 10, 2021, the parties entered into a settlement agreement that concluded the legal proceedings with SuperCom. For further details see Notes 6A(1) and 6A(2).

 

F-11

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 1 - Organization and Basis of Presentation (cont’d)

 

C. Divestiture of operations (cont’d)

 

2. On March 29, 2021 the Company entered into an agreement (the “Sale Agreement”) for the sale of 100% of the issued and outstanding share capital of its wholly owned Polish subsidiary, ASEC S.A. (“ASEC”), with Vector Software SP. Z O.O. (the “Buyer”). ASEC is headquartered in Krakow, Poland, and has been conducting the Company’s Mass Transit Ticketing business in Europe.

 

The sale of ASEC was completed on April 21, 2021. The Company has determined that the Mass Transit Ticketing business qualifies as a discontinued operation. Accordingly, the results and the cash flows of this operation for all reporting periods are presented in the statements of operations and in the statements of cash flows, respectively, as discontinued operations separately from continuing operations. In addition, assets and liabilities of the Polish subsidiary and assets and liabilities related to the Mass Transit Ticketing operation that have not yet been actually sold as of December 31, 2020, are presented as assets and liabilities held for sale in the balance sheets as of December 31, 2020.

 

The consideration for ASEC after reduction of some working capital adjustments, as agreed in April 2021, is approximately $2,700, out of which: (i) approximately $2,100 was transferred from the Buyer to ASEC at the end of March 2021 in order to repay Polish bank loans, out of which approximately $1,700 was repaid as of March 31, 2021 and a loan of approximately $400 was repaid at the beginning of April 2021 and (ii) $600 was paid by the Buyer to the Company in April 2021.

 

The Sale Agreement contains customary representations and warranties, as well as covenants, including an undertaking the Company provided not to compete with the business of ASEC for a period of five years after the closing and an undertaking to indemnify ASEC and the Buyer for certain damages. The Company’s liability is limited to the purchase price actually paid by the Buyer.

 

D. Liquidity and Capital Resources

 

The Company has had recurring losses and cash outflows from operating activities. It has an accumulated deficit as of June 30, 2021 of $228,848. As of June 30, 2021 the Company also has a payable balance on its short-term bank loans, that is due within the next 12 months, of $795 and a convertible short-term loan from shareholders, including accrued interest, of $1,661 (out of which, only amounts of $77 is presented as a liability within ‘convertible short-term loan from a controlling shareholder’), that, if not converted, would mature in December 2021 (see also Note 5).

 

Since inception, the Company’s principal sources of liquidity have been revenues, proceeds from sales of equity securities (regarding the issuance of shares during the last two years, see Note 10A), borrowings from banks, government and shareholders, including convertible loans, proceeds from the exercise of options and warrants as well as proceeds from the divestiture of parts of the Company’s businesses. The Company had cash, cash equivalents and short-term investments representing bank deposits of $2,564 (of which an amount of $105 has been pledged as security for certain items) as of June 30, 2021. 

 

F-12

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 1 - Organization and Basis of Presentation (cont’d)

 

D. Liquidity and Capital Resources (cont’d)

 

The recent situation in Poland resulting from the coronavirus (“COVID-19”) pandemic, led to an almost complete stop to the Company’s Mass Transit Ticketing sales business, which negatively impacted the Company’s cash flow. The revenues from this operation, that were relatively stable during the year preceding the COVID-19 outbreak, decreased by $295 in the first quarter of 2021 compared to the first quarter of 2020, mainly due to lockdowns and other restrictions and consequences of the COVID-19 as started in March 2020. On April 21, 2021, the Company completed the sale of ASEC, including its Mass Transit Ticketing activity, as mentioned in Note 1C(2). The results, including the revenues, and the cash flows of the Mass Transit Ticketing operation for all reporting periods are presented in the statements of operations and in the statements of cash flows, respectively, as discontinued operations separately from continuing operations.

 

The Company’s management has been working on updating the Company’s strategy for the coming years in order to realize its potential, resume its growth, and ultimately create shareholder value. The Company raised additional funds and increased its cash, cash equivalents and short-term investments on May 19, 2021, as mentioned in Note 10A(2). Additionally, a portion of additional revenue the Company was hoping to recognize in the second quarter has become backlogged due to a shortage in components, as further described below, and will be delivered later in the year. Therefore, the Company believes that it has sufficient capital resources to fund its operations for at least the next 12 months. In addition, the Company engaged an investment bank to explore strategic options and is investing resources in this process.

 

In connection with the outbreak of COVID-19, the Company has taken steps to protect its workforce in Israel, the United States, Poland, South Africa and elsewhere. Such steps include working from home where possible, minimizing face-to-face meetings, utilizing video conference as much as possible, social distancing at facilities and elimination of most international travel. The Company continues to comply with all local health directives.

 

The Company has continued to see an interest from new customers, potential customers and partners as they forecasted that the need for the Company’s products will grow, yet execution of closing is still slow due to the current business environment.

 

While interest from current and new customers is growing, which is reflected in an increasing rate of orders, a global shortage in components, which caused an increase in components prices, freight cost and longer lead-time, has created a delay in fulfilling customers’ orders which impacted the Company’s revenues and product gross margin, mainly in the Retail segment. As a response to this business environment, the Company encourages its customers to provide their forecast for their demand and continues to maintain a comprehensive network of world-wide suppliers in order to optimize its access to critical components. In addition, during last few months the Company purchased an amount of such components to be used for sales later this year. As long as the COVID-19 pandemic continues, the components’ lead-time may be longer than normal and the shortage in components may continue or get worse.

 

It is difficult to predict what other impacts the COVID-19 pandemic may have on the Company.

 

F-13

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 1 - Organization and Basis of Presentation (cont’d)

 

E. Retroactively adjustment of basic and diluted net losses attributable to shareholders per ordinary share (the “EPS”) for previous reporting periods

 

At the beginning of the second quarter of 2021, the Company offered its shareholders to purchase additional ordinary shares as part of a rights offering (the “Rights Offering”). The Rights Offering was concluded on May 19, 2021 by issuance of shares, as mentioned in Note 10A(2). The Rights Offering included an offer to all existing shareholders of the Company to purchase additional ordinary shares in consideration for a lower exercise price than the quoted share price in the active market, reflects a bonus element that is somewhat similar to a stock dividend. Therefore, basic and diluted ESP was adjusted retroactively for the bonus element for all periods presented. In computing the adjustment factor to the EPS, the Theoretical ex-rights fair value per share was computed by adding the aggregate fair value of the shares immediately prior to the exercise of the rights to the proceeds from the exercise of the rights and dividing by the number of shares outstanding after the exercise of the rights. The resulting adjusted factor was 1.069 and 1.071 for the three months and the six months ended June 30, 2020, respectively.

 

Note 2 – Significant Accounting Policies

 

Except as described in Note 2A below, these interim unaudited condensed consolidated financial statements have been prepared according to the same accounting policies as those discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

 

A. Recently Adopted Accounting Pronouncements

 

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes. This ASU, among other things, removes the exception to the incremental approach for intra-period allocation of tax expense when a company has a loss from continuing operations and income from other items that are not included in continuing operations, such as income from discontinued operations, or income recorded in other comprehensive income. The general rule under Accounting Standards Codification (“ASC”) 740-20-45-7 is that the tax effect of pretax income or loss from continuing operations should be determined by a computation that does not consider the tax effects of items that are not included in continuing operations. Previously, companies could consider the impact on a loss from continuing operations of items in discontinued operations or other comprehensive income. However, under the amended guidance, companies should not consider the effect of items outside of continuing operations in calculating the tax effect on continuing operations. The Company adopted ASU 2019-12 as of January 1, 2021. The adoption of this accounting standard did not have a material effect on our financial position, results of operations and cash flows.

 

B. Recent accounting pronouncements

 

1. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. To achieve this objective, the amendments in this ASU replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates.

 

F-14

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 2 – Significant Accounting Policies (cont’d)

 

B. Recent accounting pronouncements (cont’d)

 

1. (Cont’d)

The amendments affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. ASU 2016-13 is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted for fiscal years beginning after December 15, 2018. The Company currently does not expect the adoption of this accounting standard to have a material impact on its consolidated financial statements.

 

2. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). This pronouncement simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, the ASU simplifies accounting for convertible instruments by removing major separation models required under current accounting standard. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for it and simplifies the diluted earnings per share calculations in certain areas. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Early adoption is permitted for annual period beginning after December 15, 2020. The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements.

 

Note 3 - Other Receivables and Prepaid Expenses

 

    June 30,     December 31,  
    2021     2020  
Government institutions   $ 75     $ 104  
Prepaid expenses     277       257  
Supplier advances     730       227  
Other current receivables     (*) 1,630       107  
                 
    $ 2,712     $ 695  

 

(*) See Note 6A(2).

 

Note 4 - Other Current Liabilities

 

    June 30,     December 31,  
    2021     2020  
Employees and related expenses   $ 795     $ 516  
Accrued expenses     882       811  
Customer advances     76       142  
Short-term liabilities due to operating leases and current maturities     720       762  
Other current liabilities     (*) 1,797       52  
    $ 4,270     $ 2,283  

 

(*) See Note 6A(2).

  

F-15

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 5 – Convertible short-term loan from shareholders

 

On December 9, 2020, the Company entered into a loan financing agreement (the “Loan Agreement”), with Jerry L. Ivy, Jr., Descendants’ Trust (“Ivy”, or the “Lender”), the Company’s Controlling Shareholder (as such term is defined under the Israeli Companies Law, 5759-1999, as amended (the “Companies Law”)). The Loan Agreement provides that the Lender will extend a loan to the Company in the amount of up to $1,500 (the “Loan Amount”), payable in two tranches: one of $625 at the initial closing that took place on December 17, 2020, and the other of $875 at the second closing that took place on January 28, 2021. The amount lent under the Loan Agreement is secured pursuant to a debenture by a first priority floating charge over all the Company’s tangible or intangible assets and other property, the Company owns, subject only to certain permitted security interests, as set forth in Loan Agreement. The amount lent under the Loan Agreement and all accrued interest was scheduled to mature on June 17, 2021 (the “Initial Maturity Date”), and was to be payable in full on the Initial Maturity Date, provided that the maturity date could be extended by six months at the sole option of Ivy. The amount lent bears interest on all outstanding principal at an interest rate of 8.0% per annum, (the “Interest”); provided, however, that upon an extension of the maturity period beyond the Initial Maturity Date, the Interest will automatically increase, effective as of the Initial Maturity Date, to the rate of 10.0% per annum. Also, in case of an extension of the Initial Maturity Date, the accrued interest for the first six months for which the Loan Amount has been outstanding will be payable by the Company to the Lender at the time of the extension, and the accrued Interest for the extension period was to be payable by the Company on the extended maturity date. In addition, the Company may repay the amount lent, in whole and not in part, and any accrued Interest thereon, at any time prior to the Initial Maturity Date (as it may be extended), in its sole discretion. On March 2, 2021, the Company obtained shareholders’ approval to the grant of a right to Ivy, pursuant to which, at any time prior to the repayment in full of the amount lent, together with Interest accrued and all other amounts outstanding under the Agreement (the “Secured Amount”), Ivy will be entitled, at its sole discretion, to demand to convert (the “Conversion Right”) the entire Secured Amount into the Company’s Ordinary Shares, at a price per share equal to the lower of (a) $0.20 per share (subject to adjustment in the event of any bonus shares, combinations or splits) and (b) a price per share reflecting a discount to the average closing bid price of an Ordinary Share over the 20 trading days preceding the Initial Closing (the “Benchmark Price”) ($0.248), as follows: (i) if conversion occurs until March 17, 2021 (no later than three months after the initial closing), the conversion price per share will be $0.1984 (reflects discount of 20% of the Benchmark Price); (ii) if conversion occurs between March 18, 2021, and June 17, 2021 (more than three months but no later than six months after the initial closing), the conversion price per share will be $0.1736 (reflects discount of 30% of the Benchmark Price); (iii) if conversion occurs after June 17, 2021 (more than six months after the initial closing (to the extent extended in accordance with the terms of the Loan Agreement)), the conversion price per share will be $0.124 (reflects discount of 50% of the Benchmark Price); and (iv) if conversion occurs upon an event of default, the conversion price per share will be $0.124 (reflects discount of 50% of the Benchmark Price).

 

Pursuant to the Loan Agreement, the Conversion Right will become effective only following the approval thereof by the shareholders of the Company in accordance with the requirements of the Companies Law, which approval applies to a controlling shareholder transaction that includes a private offering that may increase the holdings of a controlling shareholder to and above 45% of the share capital of the Company, and will be deemed of no force or effect at any time prior to obtaining such Shareholders' Approval, if at all. The Company obtained such shareholders’ approval on March 2, 2021.

 

The Loan Agreement includes customary events of default, including, among others, failures to repay any amounts due to the Lender, breaches or defaults under the terms of the Agreement, etc. If an event of default occurs, the Secured Amount shall immediately become due and payable, without the need for any notice by the Lender.

 

F-16

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 5 - Convertible short-term loan from shareholders (cont’d)

 

The Loan Agreement was subsequently amended to allow for an additional lender (“the additional lender”) to lend $100 under the same terms as Ivy. Accordingly, the aggregate gross amount the Company received under the Loan Agreement is $1,600, out of which $975 took place as part of the second closing on January 28, 2021.

 

On June 17, 2021, the Lender, being the majority of the lenders, exercised its option to extend the Initial Maturity Date, and the parties entered into a notice of exercise of option and agreement (the “Extension Agreement”), according to which the maturity date was extended until December 17, 2021 (the “Extended Maturity Date”). Pursuant to both the Loan Agreement and the Extension Agreement, the interest rate automatically increased, effective as of the Initial Maturity Date, to the rate of 10.0% per annum (the “Extension Interest”). Any payment of interest is subject to withholding of taxes at source and the interest rates mentioned above are net of such withholding. The net amount of interest on the Loan Amount accrued through June 17, 2021 was approximately $55 (the “Interest Debt”). Under the Extension Agreement, it was agreed that the Interest Debt shall be payable on the Extended Maturity Date, while until then it shall be considered part of the Loan Amount and shall bear the Extension Interest rate. As of June 30, 2021, the Secured Amount is $1,661. In the event of a conversion of the Loan Amount, the Interest Debt shall convert into Ordinary Shares of the Company at the conversion price of $0.174 per share, and the remaining Secured Amount shall be converted at a price per share of $0.124, as originally contemplated under the Loan Agreement.

 

In accordance with ASC 815-15-25, Derivatives and Hedging, the conversion feature (“the conversion component”) was considered embedded derivative instrument. Since, as described above, the conversion component was required to be approved by the shareholders of the Company, the conversion

component did not qualify for the scope exception under ASC 815-10-15-74(a). Therefore, the conversion component is to be recorded separately from the loan component. The conversion component is measured both initially and in subsequent periods until obtaining the shareholders’ approval of the Conversion Right, at fair value, with changes in fair value charged to finance expenses, net.

 

The fair value of the conversion component at the initial closing, December 17, 2020, was estimated using the Trinomial model based on the assumptions, as follows:

 

Expected volatility (%)     125.2 %
Risk-free interest rate (%)     0.09 %
Expected dividend yield     0 %
Contractual term (years)     0.500  
Conversion price (US dollars per share)     0.124  
Underlying Share price (US dollars per share)     0.220  

 

Based on the Trinomial model, the fair value of the conversion component of the initial closing was $617 as of December 17, 2020. Accordingly, the loan component at the initial closing was $8 as of December 17, 2020.

 

There were no significant changes in the model assumptions as of December 31, 2020, compared to the assumptions as of December 17, 2020, as mentioned above. Therefore, the conversion component and the loan component were $617 and $8, respectively, as of December 31, 2020. Both components were presented as Convertible short-term loan from a controlling shareholder within the short-term liabilities as of December 31, 2020.

 

F-17

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 5 - Convertible short-term loan from shareholders (cont’d)

 

The fair value of the conversion component at the second closing, January 28, 2021, was estimated using the Trinomial model based on the assumptions, as follows:

 

Expected volatility (%)     103.23 %
Risk-free interest rate (%)     0.075 %
Expected dividend yield     0 %
Contractual term (years)     0.386  
Conversion price (US dollars per share)     0.124  
Underlying Share price (US dollars per share)     0.240  

 

Based on the Trinomial model, the entire proceeds of the second closing in amount of $975 were allocated to the conversion component and the residual balance of the of the loan component of the second closing is zero.

 

The table below summarizes the balances of the conversion components and the loan components of the initial closing and the second closing, as follows:

 

    Conversion component     Loan component     Total  
Initial closing   $ 617     $ 8     $ 625  
Second closing     975      
-
      975  
    $ 1,592     $        8     $ 1,600  

 

On March 2, 2021, the Company obtained shareholders’ approval of the Conversion Right. At this shareholders meeting date, the fair value of the conversion component of both the initial closing and second closing was estimated using the Trinomial model based on the assumptions, as follows:

 

Expected volatility (%)     107.34 %
Risk-free interest rate (%)     0.044 %
Expected dividend yield     0 %
Contractual term (years)     0.296  
Conversion price (US dollars per share)     0.124  
Underlying Share price (US dollars per share)     0.390  

 

The change in the fair value of the conversion component is as follows:

 

    Conversion component  
Fair value before the shareholders’ approval date   $ 1,592  
Change in fair value (*)     1,974  
Fair value at the shareholders’ approval date   $ 3,566  

 

(*) This amount is recorded as loss from change in fair value of embedded derivative as part of the financial expenses in the statements of operations of the first quarter of 2021.

 

Following the shareholders’ approval of the Conversion Right on March 2, 2021, the conversion component is qualifying for the scope exception under ASC 815-10-15-74(a). In accordance with ASC 815-15-35-4, since the embedded conversion option in the convertible debt no longer meets the bifurcation criteria, the fair value of the conversion component, in the amount of $3,566, was reclassified from short-term liability to shareholders equity at this approval date.

 

The change in the balance of the Loan component following the shareholders’ approval of the Conversion Right on March 2, 2021, is as follows:

 

    Loan component  
Balance as of March 2, 2021   $ 8  
Financial expenses     69  
Balance as of June 30, 2021   $       77  

 

F-18

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 6 - Commitments and Contingencies

 

A. Legal claims

 

1. In June 2013, prior to the Company’s divestiture of its SmartID division, Merwell Inc. (“Merwell”) filed a claim against the Company before an agreed-upon arbitrator alleging breach of contract in connection with certain commissions claimed to be owed to Merwell with respect to the division’s activities in Tanzania. These activities, along with all other activities of the SmartID division, were later assigned to and assumed by SuperCom in its purchase of the division. SuperCom undertook to indemnify the Company and hold it harmless against any liability the Company may incur in connection with Merwell’s consulting agreement and the arbitration. An arbitration decision was issued on February 21, 2016, awarding Merwell approximately $855 for outstanding commissions, plus expenses and legal fees, as well as a right to receive additional information from the Company regarding an additional engagement period in Tanzania and a right to possibly receive additional amounts from the Company, if at all, according to the information that will be provided. The arbitration decision had been appealed and the appeal was denied on June 17, 2018. In order to collect the award, Merwell filed a motion against the Company and the Nazareth District Court issued a judgment requiring the Company to pay Merwell an amount of NIS 5,080 (approximately $1,370) that was paid by the Company on January 8, 2019.

 

As mentioned above, based on the agreement with SuperCom from April 2016 (which was granted an effect of a court judgment), SuperCom was liable for all the costs and liabilities arising out of this claim. Since SuperCom failed to pay the Company the amounts due, in February 2019 the Company initiated an arbitration process to collect from SuperCom, the amount paid to Merwell, as well as any complementary amounts, as may be ordered in the future.

 

Concurrently and subject to the fulfillment of the arbitration process between the Company and SuperCom, on August 10, 2021, the parties entered into a settlement agreement that concluded the legal proceedings with SuperCom. For further details see Notes 6A(2) below.

 

2. On June 12, 2019, Merwell submitted a complementary claim against the Company in arbitration, with respect to the additional financial details that Merwell claims that the Company was ordered to provide according to the arbitration verdict from February 21, 2016, and additional payments that Merwell claims that the Company is obligated to pay Merwell. The said financial details refer to the quantity of smart driving licenses that Merwell claims were issued in the later period of a project in Tanzania in which Merwell claims to have provided services to the Company. Merwell claims that despite the Company’s failure to provide the details, Merwell obtained the details independently from other sources, and they indicate that the Company is obligated to pay Merwell an additional amount of approximately $1,618, and there might be additional amounts to be claimed in the future, as additional information might be found from time to time. On March 4, 2020, the Company submitted a response to this complementary claim, rejecting Merwell’s claims. On September 16, 2020, Merwell filed a request to amend the additional amount claimed from approximately $1,618 to approximately $3,012. As mentioned above, the Company was conducting in parallel a separate arbitration process against SuperCom in that matter, as the Company deems SuperCom to be liable for all the costs and liabilities arising out of this claim. On August 10, 2021, the Company reached settlement agreements with both Merwell and SuperCom. Both settlements are, as noted above, linked, as SuperCom was deemed liable for all costs and expenses arising out of the claim made by Merwell. As part of the settlement with Merwell, the Company paid NIS 5,700 (approximately $1,766) on August 10, 2021, and as part of the settlement with SuperCom (that concluded the legal proceedings, as mentioned in Notes 1C(1) and 6A above), the Company received NIS 5,128 (approximately $1,589) on August 10, 2021. The Financial Statements as of June 30, 2021, includes a provision in amount of $1,766 within ‘other current liabilities’ and an asset in amount of $1,589 within ‘other current receivables, in according to the settlements with Merwell and SuperCom, respectively. The loss of $177 that derives from those settlements is presented within ‘loss from discontinued operations’.

 

F-19

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 6 - Commitments and Contingencies (cont’d)

 

A. Legal claims (cont’d)

 

3. In October 2013, a financial claim was filed against the Company and its then French subsidiary, Parx France (in this paragraph, together, the “Defendants”), in the Commercial Court of Paris, France (in this paragraph, the “Court”). The sum of the claim is €1,500 (approximately $1,783) and is based on the allegation that the plaintiff sustained certain losses in connection with Defendants not granting the plaintiff exclusive marketing rights to distribute and operate the Defendants’ PIAF Parking System in Paris and the Ile of France. On October 25, 2017, the Court issued its ruling in this matter dismissing all claims against the Company but ordering Parx France to pay the plaintiff €50 ($59) plus interest in damages plus another approximately €5 ($6) in other fees and penalties. As, in accordance with the sale agreement signed between the Company and Parx France, the Company is liable and shall indemnify Parx France for any amount ruled against it as part of that claim, the Company offered to pay the amounts mentioned above to the plaintiff in consideration for not filing future appeals. The Plaintiff rejected this offer and filed an appeal against Parx France and the Company claiming the sum of €503 ($598) plus interest and expenses. On November 7, 2019, the Company’s external legal counsel concluded that the appeal was inadmissible, and that it believed that the opposing claims would be dismissed. The case was pleaded before the Court and the Court has provided a judgement, dated July 8, 2021, declaring that the appeal against the Company is null and void, and annulled the €50 ($59) damages pronounced by the previous court.

 

4. In July 2019, the Company received a request (the “Request”), to allow a petitioner to submit a class action, which concerns the petitioner’s claims that, inter alia, through the EasyPark card, drivers are permitted to exceed the quota of permitted hours in accordance with the instructions of various local authorities in Israel. The Request was submitted against a company incorporated by the buyer of the assets (including the parking activity) of the Israeli subsidiaries of the Company (the “Company’s Subsidiaries”) and against two other companies that operate technological means for payment for public parking spaces scattered throughout the cities. Since the majority of potential claims against the Company’s Subsidiaries relate to the period following the sale of the Company’s Subsidiaries’ assets, including the parking activity, it appears that the Company’s exposure through this channel is limited. Furthermore, even if payment will be required, the buyer would be liable for the majority of such payment. Therefore, the Company will not participate in such procedure at this stage. Based on the assessment of the Company’s external legal counsel, the exposure of the Company is low.

 

F-20

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 6 - Commitments and Contingencies (cont’d)

 

B. Other contingency

 

The Company has entered into several research and development agreements, pursuant to which the Company received grants from the Israel Innovation Authority (“IIA”), and is therefore obligated to pay royalties to the IIA at a rate of 3%-3.5% of its sales up to the amounts granted (linked to the U.S. dollar with annual interest at LIBOR as of the date of approval, for programs approved from January 1, 1999 and thereafter). The total amount of grants received as of June 30, 2021, net of royalties paid, was approximately $3,400 (including accrued interest). No grants from the IIA were received during the six months ended June 30, 2021 and 2020.

 

There is a dispute between the Company and the IIA in the amount of approximately NIS 3,600 ($1,104) including accrued interest (while the current debt to the IIA as presented in the Company’s financial statements amounts to approximately $156) due to a claim of the IIA about miscalculations in the amount of royalties paid by the Company and the revenues on which the Company must pay royalties. The Company has not yet completed its discussions with the IIA and intends to exhaust all options in order to resolve this matter in a favorable manner. Management believes that, at the current stage, it is more likely than not that a positive resolution will be applied to this dispute. Accordingly, no additional accrual has been recorded in the financial statements in respect of this matter.

 

During the six months ended June 30, 2021 and 2020, there were no royalty expenses.

 

C. Guarantees

 

As of June 30, 2021, the Company granted a guarantee in an amount of $105, with an expiration date in May 2024.

 

F-21

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 7 – Revenues

 

Disaggregation of revenue

 

The following tables disaggregate the Company’s revenues by major source based on categories that depict its nature and timing as reviewed by management for the three months ended June 30, 2021 and 2020:

 

    Three months ended June 30, 2021  
    Retail     Petroleum     Total  
Cashless payment products (A)   $ 1,170     $
-
    $ 1,170  
Complete cashless payment solutions (B):                        
Sales of products (B1)     807       409       1,216  
SaaS and other services (B2)     202       263       465  
      1,009       672       1,681  
Total revenues   $ 2,179     $ 672     $ 2,851  

 

    Three months ended June 30, 2020(*)  
    Retail     Petroleum     Total  
Cashless payment products (A)   $ 1,701     $
-
    $ 1,701  
Complete cashless payment solutions (B):                        
Sales of products (B1)     1,651       304       1,955  
SaaS and other services (B2)     204       177       381  
      1,855       481       2,336  
                         
Total revenues   $ 3,556     $ 481     $ 4,037  

 

(*) Reclassified to conform with the current period presentation, see Note 1C(2).

 

F-22

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 7 – Revenues (cont’d)

 

Disaggregation of revenue (cont’d)

 

The following tables disaggregate the Company’s revenues by major source based on categories that depict its nature and timing as reviewed by management for the six months ended June 30, 2021 and 2020:

 

    Six months ended June 30, 2021  
    Retail     Petroleum     Total  
Cashless payment products (A)   $ 2,694     $
-
    $ 2,694  
                         
Complete cashless payment solutions (B):                        
Sales of products (B1)     1,228       648       1,876  
SaaS and other services (B2)     539       511       1,050  
      1,767       1,159       2,926  
                         
Total revenues   $ 4,461     $ 1,159     $ 5,620  

 

    Six months ended June 30, (*) 2020  
    Retail     Petroleum     Total  
Cashless payment products (A)   $ 4,092     $
-
    $ 4,092  
                         
Complete cashless payment solutions (B):                        
Sales of products (B1)     1,930       875       2,805  
SaaS and other services (B2)     403       404       807  
      2,333       1,279       3,612  
                         
Total revenues   $ 6,425     $ 1,279     $ 7,704  

 

(*) Reclassified to conform with the current period presentation, see Note 1C(2).

 

F-23

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 7 – Revenues (cont’d)

 

Performance obligations

 

Below is a listing of performance obligations for the Company’s main revenue streams:

 

A. Cashless payment products –

 

The performance obligation is the selling of contactless payment products. Most of those products are Near Field Communication (NFC) readers. For such sales the performance obligation, transfer of control and revenue recognition occur when the products are delivered.

 

B. Complete cashless payment solutions –

 

The complete solution includes selling of products and complementary services, as follows:

 

1. Sales of products –

 

Selling of contactless payment products (see A above) together with payment gateways and machine-to-machine controllers.

 

Selling of petroleum payment solutions including site and vehicle equipment.

 

For such sales, the performance obligation, transfer of control and revenue recognition occur when the products are delivered.

 

2. SaaS and other services -

 

The types of arrangements and their main performance obligations are as follows:

 

To provide terminal management system licensing for software that is responsible for remote terminal management and cloud-based software licensing which provide data insights. For such services, the revenue recognition occurs as the services are rendered since the performance obligation is satisfied over time.

 

To provide technical and customer services for products. For such services, the performance obligation is satisfied over time and therefore revenue recognition occurs as the services are rendered.

 

The Company includes a warranty in connection with certain contracts with customers, which are not considered to be separate performance obligations. The cost to the Company of this warranty is insignificant.

 

Contract balances

 

    June 30,     December 31,  
    2021     2020  
Trade receivables, net of allowance for doubtful accounts   $ 2,139     $ 1,148  
Customer advances   $ 76     $ 142  

 

Trade receivable are recognized when the right to consideration becomes unconditional based upon contractual billing schedules.

 

F-24

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 7 – Revenues (cont’d)

 

Transaction price and variable consideration

 

The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring goods or services to a customer, excluding amounts collected on behalf of third parties. In certain arrangements with variable consideration, revenue is recognized over time as it is mainly attributed to ongoing services provided.

 

Note 8 – Discontinued operations

 

As described in Note 1C, the Company divested its interest in ASEC, including its Mass Transit Ticketing activity and the SmartID division and presented these activities as discontinued operations.

 

Set forth below are the results of the discontinued operations:

 

    Three months ended June 30,     Six months ended June 30,  
    2021     (*)2020     2021     (*)2020  
Revenues   $
-
    $ 817     $ 488     $ 1,600  
Expenses     (275 )     (1,012 )     (1,152 )     (1,888 )
Other loss, net    
(**)(922
)    
-
     
(**)(951
)    
-
 
Net loss from discontinued operations   $ (1,197 )   $ (195 )   $ (1,615 )   $ (288 )

 

(*) Reclassified to conform with the current period presentation, see Note 1C(2).

(**) Mainly including net loss of $177 due to the legal proceedings, as mentioned in Note 6A(2), and loss of $746 due to transfer of the exchange differences on translation, as derived from ASEC, from other comprehensive loss to the statement of operations loss (see statements of comprehensive loss).

 

F-25

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 8 – Discontinued operations (cont’d)

 

The following table summarizes information about assets and liabilities from discontinued operations held for sale as of December 31, 2020:

 

    December 31,  
    2020  
Assets held for sale from discontinued operations:      
Current assets:      
Cash and cash equivalents   $ 1,017  
Trade receivables, net of allowance for doubtful accounts of $42     409  
Other receivables and prepaid expenses     454  
Inventories     392  
Property, plant and equipment, net     3,136  
Intangible assets, net     370  
Right-of-use assets due to operating leases     580  
      6,358  
         
Liabilities held for sale from discontinued operations:        
Current liabilities:        
Short-term bank credit and current maturities of long-term loans     2,339  
Trade payables     1,832  
Other current liabilities     443  
Long-term loans, net of current maturities (*)     642  
Long-term liabilities due to operating leases, net of current maturities (*)     401  
Deferred tax liability     172  
      5,829  

 

(*) Those liabilities were received for a long-term (more than twelve months) in ASEC, but were presented as held for sale within the current assets as of December 31, 2020, because the Company has determined that the sale of ASEC qualified as held for sale and as a discontinued operation as of  December 31, 2020.

 

F-26

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 9 - Fair Value of Financial Instruments

 

The Company’s financial instruments consist mainly of cash and cash equivalents, short-term interest bearing investments, accounts receivable, restricted deposits for employee benefits, accounts payable and short-term and long-term loans.

 

Fair value for the measurement of financial assets and liabilities is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The Company utilizes a valuation hierarchy for disclosure of the inputs for fair value measurement. This hierarchy prioritizes the inputs into three broad levels as follows:

 

  Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

 

  Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

 

  Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

 

By distinguishing between inputs that are observable in the market place, and therefore more objective, and those that are unobservable and therefore more subjective, the hierarchy is designed to indicate the relative reliability of the fair value measurements. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

 

The Company, in estimating fair value for financial instruments, determined that the carrying amounts of cash and cash equivalents, trade receivables, short-term bank credit and trade payables are equivalent to, or approximate their fair value due to the short-term maturity of these instruments. The carrying amounts of variable interest rate long-term loans are equivalent or approximate to their fair value as they bear interest at approximate market rates. The liabilities held for sale as of December 31, 2020, included a long-term loan, that did not bear any interest, but taking into account the schedule of its maturities, its amount and the relatively low market rates, the difference between its carrying amount and its fair value was insignificant.

 

As of June 30, 2021, the Company held approximately $1,605 of short-term bank deposits (as of December 31, 2020 - $105). As of June 30, 2021 and December 31, 2020, a short-term deposit in the amount of $105 has been pledged as security in respect of guarantees granted and cannot be pledged to others or withdrawn without the consent of the bank.

 

Derivatives

 

Embedded derivatives are separated from the host contract and carried at fair value when (1) the embedded derivative possesses economic characteristics that are not clearly and closely related to the economic characteristics of the host contract and (2) a separate, standalone instrument with the same terms would qualify as a derivative instrument. The derivative is measured both initially and in subsequent periods at fair value, with changes in fair value charged to financial expenses, net. As to embedded derivatives arising from the issuance of convertible debentures, see Note 5. Transaction expenses related to the embedded derivatives are recognized as financial expenses at the date of the initial recognition.

 

F-27

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 10 – Equity

 

A. Share capital

 

1. On December 23, 2019, the Company entered into a share purchase agreement (the “Agreement”) with Ivy and two other investors (collectively together with Ivy – “Investors”). The Agreement relates to a private placement of an aggregate of up to 12,500,000 ordinary shares of the Company for aggregate gross proceeds to the Company of up to $2,500.

 

As part of this Agreement, in December 2019 and January 2020, the Company issued 5,460,000 and 1,040,000 ordinary shares, respectively, for aggregate gross proceeds of $1,092 and $208, respectively. Under the term of the Agreement and following the issuance of those shares, the Company appointed one representative to its Board of Directors (the “Board”), designated by Ivy. Also, pursuant to the Agreement, Ivy has a right to purchase any future equity securities offered by the Company, except with respect to certain exempt issuances as set forth in the Agreement.

 

The issuance of the remaining 6,000,000 ordinary shares (the “Subsequent Closing”) for aggregate gross proceeds of $1,200 took place in April 2020, following the approval by the Company’s shareholders on April 14, 2020, of the resolutions detailed below, that were required for the consummation of the Subsequent Closing under the Agreement and the applicable law: (i) an increase in the number of the ordinary shares authorized for issuance from 50,000,000 to 100,000,000; (ii) the issuance of the ordinary shares to Ivy following which Ivy will hold 25% or more of the total voting rights at general meetings of the shareholders of the Company; and (iii) the election of the representative designated by Ivy to the Board.

 

The issuance costs were approximately $31, $8 and $111 during the three months ended June 30, 2020, March 31, 2020, and December 31, 2019, respectively.

 

In addition, pursuant to the terms of the Agreement, on May 5, 2020, after the consummation of the Subsequent Closing, the Board appointed an additional representative designated by Ivy. The appointment of such designee shall remain valid through the next general meeting of the Company’s shareholders or as set forth in the Articles of Association of the Company.

 

2. During the second quarter of 2021 the Company conducted a rights offering (the “Rights Offering”), under which the Company offered its shareholders the ability to exercise subscription rights and purchase, for every subscription right held by them as of April 14, 2021 (i.e. the record date), one Ordinary Share of the Company, at a purchase price of $0.174 per share.

 

The Rights Offering was concluded on May 19, 2021 and was oversubscribed. Accordingly, the Company issued an aggregate of 18,965,516 Ordinary Shares (the “Issued Shares”) for aggregate gross proceeds to the Company of $3,300. The Issued Shares included 10,869,304 shares that were issued to Ivy and its affiliates, upon exercise of its basic subscription rights and over-subscription rights. Following the Rights Offering, Ivy and its affiliates own 35.9% of issued and outstanding share capital as of June 30, 2021.

 

The issuance costs derived from the Rights Offering were approximately $128.

 

3. Ivy has an existing right to purchase additional shares from the Company upon conversion of a convertible loan – See Note 5.

 

F-28

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 10 – Equity (cont’d)

 

B. Stock option plans

 

During each of the six month periods ended June 30, 2021 and June 30, 2020, 640,000 and 814,000 options were granted, respectively. The vesting period for the options is three years. The average exercise prices for the options that were granted during the six months ended June 30, 2021 and June 30, 2020 are $0.23 and $0.24, respectively. Those options expire up to five years after the date of grant. Any options which are forfeited or cancelled before expiration become available for future grants under the Company’s option plan. The fair value of each option granted to employees during the six months ended June 30, 2021 and June 30, 2020 was estimated on the date of grant, using the Black-Scholes model and the following assumptions:

 

    Six months ended June 30,  
    2021     2020  
Expected dividend yield     0 %     0 %
Expected volatility     113 %     107 %
Risk-free interest rate     0.17 %     0.36 %
Expected life - in years     2.50       2.49  

 

1. Dividend yield of zero percent for all periods.
2. Expected average volatility represents a weighted average standard deviation rate for the price of the Company’s ordinary shares on Nasdaq and on the OTCQX market, as applicable.
3. Risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant.
4. Estimated expected lives are based on historical grants data.

 

The Company’s options activity (including options to non-employees) and options outstanding and options exercisable as of December 31, 2020 and June 30, 2021, are summarized in the following table:

 

    Number of options outstanding     Weighted average exercise price per share  
Outstanding – December 31, 2020     1,443,333     $ 0.54  
Options granted     640,000       0.23  
Options expired or forfeited     (117,000 )     0.72  
Outstanding – June 30, 2021     1,966,333       0.43  
Exercisable as of:                
December 31, 2020     681,330     $ 0.83  
June 30, 2021     714,346     $ 0.74  

 

The weighted average fair value of options granted during the six months ended June 30, 2021 and during the six months ended June 30, 2020 is $0.14 and $0.12, respectively, per option. The aggregate intrinsic value of outstanding options as of June 30, 2021 and December 31, 2020 is approximately $65 and $5, respectively. The aggregate intrinsic value of exercisable options as of June 30, 2021 and December 31, 2020 $12 and $2, respectively.

 

F-29

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 10 – Equity (cont’d)

 

B. Stock option plans (cont’d)

 

The following table summarizes information about options outstanding and exercisable (including options to non-employees) as of June 30, 2021:

 

    Options outstanding    

Options exercisable

 
Range of exercise price ($)   Number Outstanding as of
June 30,
2020
    Weighted average remaining contractual life (years)     Weighted Average Exercise Price     Number Outstanding As of
June 30,
2020
    Weighted average remaining contractual life (years)     Weighted Average Exercise Price  
0.20-0.90     1,610,333       3.95       0.27       358,346       3.45       0.35  
1.07-1.22     356,000       0.85       1.13       356,000       0.85       1.13  
      1,966,333       3.39               714,346       2.16          

 

As of June 30, 2021, there was approximately $153 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of approximately 1.41 years.

 

During the three months ended June 30, 2021 and June 30, 2020, the Company recorded stock-based compensation expenses in the amount of $15 and $16, respectively, in accordance with ASC 718, Compensation-Stock Compensation.

 

During the six months ended June 30, 2021 and June 30, 2020, the Company recorded stock-based compensation expenses in the amount of $29 and $28, respectively, in accordance with ASC 718, Compensation-Stock Compensation.

 

C. Stock options, including shares that Could derive from a convertible short-term loan from shareholders, as mentioned in Note 5, in the amounts of 15,217,536 and 1,593,000 outstanding as of June 30, 2021 and 2020, respectively, have been excluded from the calculation of the diluted net loss per ordinary share because all such securities have an anti-dilutive effect for all periods presented.

 

D. As for the newly adopted Equity Incentive Plan, as approved subsequent the balance sheet date, see Note 13.

  

F-30

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 11 - Operating segments

 

For the purposes of allocating resources and assessing performance in order to improve profitability, the Company’s chief operating decision maker (“CODM”) examines two segments which are the Company’s strategic business units: (1) Retail, and (2) Petroleum.

 

Information regarding the results of each reportable segment is included below based on the internal management reports that are reviewed by the CODM.

 

    Three months ended June 30, 2021  
    Retail     Petroleum     Total  
                   
Revenues   $ 2,179     $           672     $ 2,851  
                         
Reportable segment gross profit (**)     587       400       987  
                         
Reconciliation of reportable segment                        
gross profit to gross profit for the period                        
                         
Depreciation                     (9 )
Stock-based compensation                     (1 )
                         
Gross profit for the period in the consolidated financial statement                   $ 977  

 

    Three months ended June 30, 2020 (*)  
    Retail     Petroleum     Total  
                   
Revenues   $ 3,556     $ 481     $ 4,037  
                         
Reportable segment gross profit (**)     1,425       264       1,689  
                         
Reconciliation of reportable segment                        
gross profit to gross profit for the period                        
                         
Depreciation                     (9 )
Stock-based compensation                     (1 )
                         
Gross profit for the period in the consolidated financial statement                   $ 1,679  

 

(*) Reclassified to conform with the current period presentation, see Note 1C(2).

(**) Gross profit as reviewed by the CODM, represents gross profit, adjusted to exclude depreciation and stock-based compensation.

 

F-31

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 11 - Operating segments (cont’d)

 

    Six months ended June 30, 2021  
    Retail     Petroleum     Total  
                   
Revenues   $ 4,461     $ 1,159     $ 5,620  
                         
Reportable segment gross profit (**)     1,766       633       2,399  
                         
Reconciliation of reportable segment gross profit to gross profit for the period                        
                         
Depreciation                     (17 )
Stock-based compensation                     (2 )
                         
Gross profit for the period in the consolidated financial statement                   $ 2,380  

 

    Six months ended June 30, 2020 (*)  
    Retail     Petroleum     Total  
                   
Revenues   $ 6,425     $ 1,279     $ 7,704  
                         
Reportable segment gross profit (**)     2,758       587       3,345  
                         
Reconciliation of reportable segment gross profit to gross profit for the period                        
                         
Depreciation                     (18 )
Stock-based compensation                     (2 )
                         
Gross profit for the period in the consolidated financial statement                   $ 3,325  

 

(*) Reclassified to conform with the current period presentation, see Note 1C(2).

(**) Gross profit as reviewed by the CODM, represents gross profit, adjusted to exclude depreciation and stock-based compensation.

 

F-32

 

 

On Track Innovations Ltd.

and Subsidiaries

 

Notes to the Interim Unaudited Condensed Consolidated Financial Statements

 

US dollars, NIS and Euro in thousands, except share and per share data

 

Note 12 – Balances and transactions with related parties

 

Regarding balances and transactions with a related party, Ivy, a controlling shareholder, during the reporting period, see Notes 5 and 10A.

 

Note 13 – Subsequent events

 

1. On July 19, 2021, and July 23, 2021, each of the compensation committee of the Board (the “Committee”) and the Board approved a new incentive plan (the “Equity Incentive Plan”), as mentioned in Note 10D, and further contingently approved, subject to filing of the Equity Incentive Plan and signing of appropriate grant documents by the grantees, of grants of 3.9 million stock units (“RSU Awards”) to employees pursuant to the Equity Incentive Plan. The RSU Awards will vest over a three-year vesting period, such that a 1/3 of the RSU Award shall vest each year. An RSU Award to the Company’s Chief Executive Officer is subject, in addition to the conditions set forth above, to the approval of the amended compensation policy in the upcoming annual general meeting of the shareholders of the Company.

 

The Company does not plan to issue any additional securities under its 2001 Stock Option Plan. The company plans to offer employees that were granted with options, as part of the 2001 Stock Option Plan, to forfeit their outstanding options, as mentioned in Note 10B, in exchange for grant of RSU to be granted in accordance with the Equity Incentive Plan.

 

2. Regarding settlement agreements with both Merwell and SuperCom, dated August 10, 2021, and its impact on the Financial Statements as of June 30, 2021, see Note 6A(2).

 

F-33

 

 

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Forward - Looking Statements

 

The statements contained in this Quarterly Report on Form 10-Q, or Quarterly Report, that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as “believes,” “intends,” “plans”, “expects,” “may,” “will,” “should,” or “anticipates” or the negative thereof or other variations thereon or comparable terminology, and similar expressions are intended to identify forward-looking statements. We remind readers that forward-looking statements are merely predictions and therefore are inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity, or our achievements, or industry results, to be materially different from any actual future results, performance, levels of activity, or our achievements, or industry results, expressed or implied by such forward-looking statements. Such forward-looking statements may appear in this Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as elsewhere in this Quarterly Report and include, among other statements, statements regarding the following:

 

any impact of the Corona Virus, or COVID-19, pandemic on our business and cash flow, including timing of receipt of orders, revenue recognition, payment from our customers and gross margin;

 

future sources of revenue, ongoing relationships with current and future business partners, distributors, suppliers, customers, end-user customers and resellers;

 

future costs and expenses and adequacy of capital resources;

 

our expectations regarding our short-term and long-term capital requirements and satisfaction thereof;

 

the impact of ongoing litigation on our business;

 

interest from current and new customers and rate or orders

 

the global shortage in components and the related effects of an increase in components’ prices, freight cost and longer lead-times;

 

our outlook for the coming months; and

 

plans and strategies for our business.

 

The factors discussed herein and in those risk factors expressed below and from time to time in our press releases or filings with the Securities and Exchange Commission, or the SEC, could cause actual results and developments to be materially different from those expressed in or implied by such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak and are made only as of the date of this filing.

 

Our business and operations are subject to substantial risks, which increase the uncertainty inherent in the forward-looking statements contained in this Quarterly Report. Except as required by law, we undertake no obligation to release publicly the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Further information on potential factors that could affect our business is described, among others, under the heading “Risk Factors” below and in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC. Readers are also urged to carefully review and consider the various disclosures we have made in that report.

 

As used in this Quarterly Report, the terms “we”, “us”, “our”, “the Company”, and “OTI” mean On Track Innovations Ltd. and our subsidiaries, unless otherwise indicated or as otherwise required by the context.

 

All figures in this Quarterly Report are stated in United States dollars, unless otherwise specified herein.

 

2

 

 

Overview

 

We are a leading developer of contactless payment solutions, Near Field Communication (NFC) technology based, for the unattended market. We have been a technology leader since 1990, providing systems, devices and services to operators and integrators with solutions and components that are simple to implement.

 

To date, we have deployed over one million payment solutions to our focused unattended markets: self-service kiosk, micro-markets and vending machines, entertainment and gaming, automated teller machines, Mass Transit Ticketing Validation and fuel payments.

 

We operate through regional offices, supporting clients and payment industry partners with its unique contactless payment solutions.

 

On April 21, 2021, we sold our Polish subsidiary, ASEC S.A., or ASEC, including our Mass Transit Ticketing activity in Poland. The consideration for the sale of ASEC was agreed to equal $3 million, of which approximately $2.1 million was used to repay Polish bank loans, and which was reduced by an agreed amount of approximately $300,000 due to working capital adjustments. Following this sale, we operate in two segments: (1) Retail, and (2) Petroleum.

 

In addition, we engaged an investment bank to explore strategic options and are investing resources in this process.

 

This discussion and analysis should be read in conjunction with our interim condensed consolidated financial statements and notes thereto contained in “Item 1. Financial Statements” of this Quarterly Report and our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC.

 

Results of Operations

 

Discontinued operations. In April 2021, we completed the sale of 100% of the issued and outstanding share capital of ASEC. ASEC is headquartered in Krakow, Poland and had been conducting our Mass Transit Ticketing business in Poland (which was attributed to our “Retail and Mass Transit Ticketing” segment). In December 2013, we completed the sale of certain assets, certain subsidiaries and IP directly related to our SmartID division. Accordingly, the results and the cash flows from such operations for all reporting periods are presented in the statements of operations and in the statements of cash flows, respectively, as discontinued operations separately from continuing operations. All the data in this Quarterly Report that are derived from our financial statements, unless otherwise specified, exclude the results of those discontinued operations.

 

Three months ended June 30, 2021, compared to the three months ended June 30, 2020

 

Sources of Revenue

 

We have historically derived a substantial majority of our revenues from the sale of our products, including both complete systems and original equipment manufacturer components, and, less significantly, from engineering services, customer services and technical support. In addition, we have derived revenues from Software as a Service, or SaaS. During the three months ended June 30, 2021 and June 30, 2020, the revenues that we derived from those sources were as follows (in thousands): 

 

   

Three months ended June 30,

 
    2021     2020  
Sales   $ 2,446     $ 3,751  
SaaS   $ 405     $ 286  
Total revenues   $ 2,851     $ 4,037  

 

3

 

 

Sales. Sales decreased by $1.3 million, or 35%, in the three months ended June 30, 2021, compared to the three months ended June 30, 2020. The decrease is mainly attributed to a decrease of Retail segment sales in the Asia-Pacific region, or APAC, and Europe, partially offset by an increase in Petroleum segment sales in Africa.

 

SaaS. SaaS revenues include monthly payments for a set of different software applications such as Terminal Management Systems, Payment gateway, and other software applications for the Retail segment, and a separate set of applications for fuel management systems supporting the Petroleum segment. Our SaaS revenues increased by $119,000, or 42%, in the three months ended June 30, 2021, compared to the three months ended June 30, 2020. The increase is mainly attributed to an increase in revenues in both our Retail segment and our Petroleum segment.

 

We have historically derived revenues from different geographical areas. The following table sets forth our revenues, by dollar amount (in thousands) and as a percentage of quarterly revenues in different geographical areas, in the three months ended June 30, 2021 and June 30, 2020:

 

Three months ended June 30,   Americas     Europe     Africa     APAC  
2021   $ 824       29 %   $ 1,174       41 %   $ 451       16 %   $ 402       14 %
2020   $ 810       20 %   $ 1,328       33 %   $ 237       6 %   $ 1,662       41 %

 

Our revenues from sales in the Americas in the three months ended June 30, 2021, compared to the three months ended June 30, 2020, remained consistent.

 

Our revenues from sales in Europe decreased by $154,000, or 12%, in the three months ended June 30, 2021, compared to the three months ended June 30, 2020, mainly due to a decrease in Retail sales.

 

Our revenues from sales in Africa increased by $214,000, or 90%, in the three months ended June 30, 2021, compared to the three months ended June 30, 2020, mainly due to an increase in revenues from the Petroleum segment.

 

Our revenues from sales in APAC decreased by $1.3 million, or 76%, in the three months ended June 30, 2021, compared to the three months ended June 30, 2020, mainly due to a decrease in Retail sales.

 

Our revenues derived from outside the United States are primarily received in currencies other than the U.S. dollar and accordingly have a varying impact upon our total revenues as a result of fluctuations in exchange rates.

 

The following table sets forth our revenues by dollar amount (in thousands) and as a percentage of revenues by segments, during the three months ended June 30, 2021 and June 30, 2020:

 

Three months ended June 30,   Retail     Petroleum  
2021   $ 2,179       76 %   $ 672       24 %
2020   $ 3,556       88 %   $ 481       12 %

  

Our revenues from Retail in the three months ended June 30, 2021 decreased by $1.4 million, or 39%, compared to the three months ended June 30, 2020, mainly attributed to a decrease in Retail sales in the APAC and European markets.

 

4

 

 

Our revenues from Petroleum in the three months ended June 30, 2021 increased by $191,000, or 40%, compared to the three months ended June 30, 2020, mainly due to an increase in revenues from the Petroleum segment in Africa.

 

Cost of Revenues and Gross Margin

 

Our cost of revenues, presented by gross profit and gross margin percentage, in the three months ended June 30, 2021 and June 30, 2020 were as follows (dollar amounts in thousands):

 

Cost of revenues   Three months ended June 30,  
    2021     2020  
Cost of sales   $ 1,874     $ 2,358  
Gross profit   $ 977     $ 1,679  
Gross margin percentage     34 %     42 %

 

Cost of sales. Cost of sales consists primarily of materials, as well as salaries, fees to subcontractors, related costs of our technical staff that assemble our products and freight expenses. The decrease of $484,000, or 20%, in the three months ended June 30, 2021, compared to the three months ended June 30, 2020, resulted primarily from a decrease in sales.

 

Gross margin. The decrease in gross margin in the three months ended June 30, 2021, compared to the three months ended June 30, 2020, is mainly attributed to an increase of components costs due to a components shortage as part of the impact of COVID-19 pandemic and in lesser degree due to revenue mix.

 

Operating expenses

 

Our operating expenses in the three months ended June 30, 2021 and June 30, 2020 were as follows (in thousands):

 

Operating expenses   Three months ended June 30,  
    2021     2020  
Research and development   $ 900     $ 903  
Selling and marketing   $ 736     $ 885  
General and administrative   $ 735     $ 698  
Total operating expenses   $ 2,371     $ 2,486  

 

Research and development. Our research and development expenses consist primarily of the salaries and related expenses of our research and development staff, as well as subcontracting expenses. Our research and development, in the three months ended June 30, 2021, compared to the three months ended June 30, 2020, remained consistent.

 

Selling and marketing. Our selling and marketing expenses consist primarily of salaries and substantially all of the expenses of our sales and marketing for the subsidiaries and offices in the United States, South Africa and Europe, as well as expenses related to advertising, professional expenses, participation in exhibitions and tradeshows and a change in allowance for doubtful accounts. The decrease of $149,000, or 17%, in the three months ended June 30, 2021, compared to the three months ended June 30, 2020, is primarily attributed to a decrease in employment expenses and professional expenses.

 

General and administrative. Our general and administrative expenses consist primarily of salaries and related expenses of our executive management and financial and administrative staff. These expenses also include costs of our professional advisors (such as legal and accounting), office expenses and insurance. The increase of $37,000, or 5%, in the three months ended June 30, 2021, compared to the three months ended June 30, 2020, is primarily attributed to an increase in professional expenses, partially offset by a decrease in employment expenses.

 

5

 

 

Financing expenses, net

 

Our financing expenses, net, in the three months ended June 30, 2021 and June 30, 2020 were as follows (in thousands):

 

    Three months ended June 30,  
    2021     2020  
Financing expenses, net   $ (131 )   $ (109 )

 

Financing expenses consist primarily of interest payable on loans, bank commissions and foreign exchange losses. Financing income consists primarily of foreign exchange gains and interest earned on investments in short-term deposits. The increase in financing expenses, net, of $22,000, or 20%, in the three months ended June 30, 2021, compared to the three months ended June 30, 2020, is mainly due to interest expenses as a result of a convertible loan from shareholders.

 

Net loss from continuing operations

 

Our net loss from continuing operations in the three months ended June 30, 2021 and June 30, 2020 was as follows (in thousands):

 

    Three months ended June 30,  
    2021     2020  
Net loss from continuing operations   $ (1,525 )   $ (928 )

 

The increase in the net loss from continuing operations of $597,000, or 64%, in the three months ended June 30, 2021, compared to the three months ended June 30, 2020, is mainly due to a decrease in our gross profit, partially offset by a decrease in our operating expenses, as described above.

 

Net loss from discontinued operations

 

Our net loss from discontinued operations in the three months ended June 30, 2021 and June 30, 2020 was as follows (in thousands):

 

    Three months ended June 30,  
    2021     2020  
Net loss from discontinued operations   $ (1,197 )   $ (195 )

 

Our net loss from discontinued operations for the reporting periods is presented in the statements of operations as discontinued operations separately from continuing operations. The increase in the net loss from discontinued operations of $1.0 million, or 514%, in the three months ended June 30, 2021, compared to the three months ended June 30, 2020, is mainly due to classification in an amount of $746,000 of exchange differences on translation from other comprehensive loss to net loss from discontinued operations due to completion of sale of ASEC in the second quarter of 2021, and net expenses relating to the settlement of the litigation processes with Merwell Inc. and SuperCom Ltd.

 

Net loss

 

Our net loss in the three months ended June 30, 2021 and June 30, 2020 was as follows (in thousands):

 

    Three months ended June 30,  
    2021     2020  
Net loss   $ (2,722 )   $ (1,123 )

 

6

 

 

The increase in net loss of $1.6 million or 143%, in the three months ended June 30, 2021, compared to the three months ended June 30, 2020, is mainly due to a decrease in our gross profit and an increase in net loss from discontinued operations, partially offset by a decrease in our operating expenses, as described above.

 

Six months ended June 30, 2021 compared to six months ended June 30, 2020

 

Sources of Revenue

 

During the six months ended June 30, 2021 and June 30, 2020, our revenues were as follows (in thousands):

 

   

Six months ended June 30,

 
    2021     2020  
Sales   $ 4,833     $ 7,094  
SaaS   $ 787     $ 610  
Total revenues   $ 5,620     $ 7,704  

 

Sales. Sales decreased by $2.3 million, or 32%, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020. The decrease is mainly attributed to a decrease of Retail segment sales in APAC, the Americas and Europe.

 

SaaS. Our SaaS revenues increased by $177,000, or 29%, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020. The increase is mainly attributed to an increase in revenues of both our Retail segment and our Petroleum segment.

 

The following table sets forth our revenues, by dollar amount (in thousands) and as a percentage of revenues in different geographical areas, in the six months ended June 30, 2021 and June 30, 2020:

 

Six months ended June 30,   Americas     Europe     Africa     APAC  
2021   $ 1,698       30 %   $ 2,087       37 %   $ 819       15 %   $ 1,016       18 %
2020   $ 2,565       33 %   $ 2,510       33 %   $ 754       10 %   $ 1,875       24 %

  

Our revenues from sales in the Americas decreased by $867,000, or 34%, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020, mainly due to a decrease in sales of readers to the U.S. market.

 

Our revenues from sales in Europe decreased by $423,000, or 17%, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020, mainly due to a decrease in Retail sales.

 

Our revenues from sales in Africa increased by $65,000, or 9%, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020, mainly due to an increase in revenues of Petroleum segment.

 

Our revenues from sales in APAC decreased by $859,000, or 46%, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020, mainly due to a decrease in Retail sales.

 

Our revenues derived from outside the United States are primarily received in currencies other than the U.S. dollar and accordingly have a varying impact upon our total revenues as a result of fluctuations in exchange rates.

 

7

 

 

The following table sets forth our revenues by dollar amount (in thousands) and as a percentage of revenues by segments, during the six months ended June 30, 2021 and June 30, 2020: 

 

Six months ended June 30,   Retail     Petroleum  
2021   $ 4,461       79 %   $ 1,159       21 %
2020   $ 6,425       83 %   $ 1,279       17 %

 

Our revenues from Retail in the six months ended June 30, 2021 decreased by $2.0 million, or 31%, compared to the six months ended June 30, 2020, mainly attributed to a decrease in Retail sales in APAC, the United States and Europe.

 

Our revenues in the six months ended June 30, 2021 from Petroleum decreased by $120,000, or 9%, compared to the six months ended June 30, 2020, mainly due to a decrease in sales of Petroleum products in APAC and the Americas, partially offset by an increase in SaaS revenues of Petroleum in Africa.

 

Cost of Revenues and Gross Margin

 

Our cost of revenues, presented by gross profit and gross margin percentage, in the six months ended June 30, 2021 and June 30, 2020 were as follows (dollar amounts in thousands):

 

    Six months ended June 30,  
    2021     2020  
Cost of sales   $ 3,240     $ 4,379  
Gross profit   $ 2,380     $ 3,325  
Gross margin percentage     42 %     43 %

 

Cost of sales. The decrease of $1.1 million, or 26%, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020, resulted primarily from a decrease in sales.

 

Gross margin. the decrease of gross margin percentage in the six months ended June 30, 2021, compared to the six months ended June 30, 2020, is mainly attributed to an increase of components costs due to a components shortage as part of the impact of COVID-19 pandemic, partially offset by change in our revenue mix.

 

Operating expenses

 

Our operating expenses in the six months ended June 30, 2021 and June 30, 2020 were as follows (in thousands):

 

Operating expenses   Six months ended June 30,  
    2021     2020  
Research and development   $ 1,738     $ 1,796  
Selling and marketing   $ 1,341     $ 1,583  
General and administrative   $ 1,481     $ 1,500  
Total operating expenses   $ 4,560     $ 4,879  

 

Research and development. The decrease of $58,000, or 3%, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020, is primarily attributed to a decrease in subcontracting expenses, partially offset by an increase in employment expenses.

 

Selling and marketing. The decrease of $242,000, or 15%, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020, is primarily attributed to a decrease in employment expenses and professional expenses.

 

General and administrative. The decrease of $19,000, or 1%, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020, is primarily attributed to a decrease in employment expenses, partially offset by an increase in professional expenses.

 

8

 

 

Financing (expenses) income, net

 

Our financing (expenses) income, net, in the six months ended June 30, 2021 and June 30, 2020 were as follows (in thousands):

 

    Six months ended June 30,  
    2021     2020  
Loss from change in fair value of embedded derivative   $ (1,974 )   $ -  
Other financial (expenses) income, net     (127 )   $ 67  
Financing (expenses) income, net     (2,101 )   $ 67  

 

The change in financing (expenses) income, net, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020, of $2.2 million, is mainly due to a loss from change in the fair value of embedded derivative as a result of the convertible loan of $2.0 million and to a lesser degree from interest expenses as a result of loan from shareholders and exchange rate differential.

 

Net loss from continuing operations

 

Our net loss from continuing operations in the six months ended June 30, 2021 and June 30, 2020 was as follows (in thousands):

 

    Six months ended June 30,  
    2021     2020  
Net loss from continuing operations   $ (4,268 )   $ (1,504 )

  

The increase in net loss from continuing operations of $2.8 million, or 184%, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020, is mainly due to a decrease in our sales, a decrease in our gross profit and an increase in our financing expenses, net, and due to a loss from change in fair value of embedded derivative, partially offset by a decrease in our operating expenses, as described above.

 

Net loss from discontinued operations

 

Our net loss from discontinued operations in the six months ended June 30, 2021 and June 30, 2020 was as follows (in thousands):

 

    Six months ended June 30,  
    2021     2020  
Net loss from discontinued operations   $ (1,615 )   $ (288 )

 

Our net loss from discontinued operations for the reporting periods are presented in the statements of operations as discontinued operations separately from continuing operations. The increase in the net loss from discontinued operations of $1.3 million, or 461%, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020, is mainly due to classification in an amount of $746,000 of exchange differences on translation from other comprehensive loss to net loss from discontinued operations due to completion of sale of ASEC in the six months ended on June 30, 2021, and net expenses relating to the settlement of the litigation processes with Merwell Inc. and SuperCom Ltd.

 

9

 

 

Net loss

 

Our net loss in the six months ended June 30, 2021 and June 30, 2020 was as follows (in thousands):

 

    Six months ended June 30,  
    2021     2020  
Net loss   $ (5,883 )   $ (1,792 )

  

The increase in net loss of $4.1 million, or 283%, in the six months ended June 30, 2021, compared to the six months ended June 30, 2020, is primarily due to a decrease in our gross profit, an increase in our financing expenses, net, due to a loss from change in fair value of embedded derivative and an increase in net loss from discontinued operations, partially offset by a decrease in our operating expenses, as described above.

 

Liquidity and Capital Resources

 

Our principal sources of liquidity since our inception have been revenues, proceeds from sales of equity securities, borrowings from banks, governments and shareholders, including convertible loans, proceeds from the exercise of options and warrants as well as proceeds from the divestiture of parts of our businesses.We have had recurring losses and cash outflows from operating activities. As of June 30, 2021, we had cash, cash equivalents and short-term investments representing bank deposits of $2.6 million (of which an amount of $105,000 has been pledged as security for certain items).

 

The recent situation in Poland resulting from the COVID-19 pandemic led to an almost complete stop to our Mass Transit Ticketing sales business, which negatively impacted our cash flow since March 2020. On April 21, 2021, we completed the sale of our wholly owned Polish subsidiary, ASEC, including our Mass Transit Ticketing activity. The consideration for the sale of ASEC was agreed to equal $3 million, of which approximately $2.1 million was used to repay Polish bank loans and was reduced by approximately $300,000 due working capital adjustments.

 

On December 9, 2020 and January 2021, we entered into a loan financing agreement, or the Loan Agreement, with Jerry L. Ivy, Jr., Descendants’ Trust, or the Lender. The Lender is our controlling shareholder. The Loan Agreement was amended on January 26, 2021, to allow for an additional lender to join the Lender and lend an additional $100,000 and provides that the Lender and the additional lender will extend us a loan in the aggregate amount of up to $1,600,000, or the Loan Amount. The Loan Agreement, before it was amended, was further described in the Current Report on Form 8-K filed by the Company on December 15, 2020. The Loan Agreement provides, among other things, that the Loan Amount and all accrued interest, or the Secured Amount, matures upon the lapse of six months following the initial closing, i.e., on June 17, 2021, or the Maturity Date, and will be payable in full on the Maturity Date, provided that the maturity date can be extended, in respect of the Loan Amount, at the sole option of the majority of the lenders. On June 17, 2021, the Lender, being the majority of the lenders, exercised its option to extend the maturity date, and the parties entered into a notice of exercise of option and agreement, or the Extension Agreement, according to which the maturity date was extended until December 17, 2021, or the Extended Maturity Date, and the Extended Maturity Period, as applicable. The Loan Amount has been bearing interest on all outstanding principal at an interest rate of 8.0% per annum. The net amount of interest on the Loan Amount accrued through June 17, 2021 was $54,849, or the Interest Debt. Pursuant to the Extension Agreement, the interest rate will automatically increase, effective as of the Maturity Date, to the rate of 10.0% per annum, or the Extension Interest. Any payment of interest is subject to withholding of taxes at source and the interest rates mentioned above are net of such withholding. Under the Extension Agreement, it was agreed that the Interest Debt shall be payable on the Extended Maturity Date, while until then it shall be considered part of the Loan Amount and shall bear the Extension Interest rate. In the event of a conversion of the Loan amount, the Interest Debt shall convert into our ordinary shares at the conversion price of $0.174 per share, and the remaining Secured Amount shall be converted at a price per share of $0.124, as originally contemplated under the Loan Agreement.

 

Our management has been working on updating our strategy for the coming years in order to realize our potential and resume our growth, and ultimately create shareholder value. We raised additional funds and increased our cash, cash equivalents and short-term investments in a gross amount of $3.3 million by closing a rights offering, or the Rights Offering, on May, 19, 2021, under which we offered our existing shareholders to purchase additional ordinary shares in consideration for a lower exercise price than the quoted share price in the active market, reflecting a bonus element that is somewhat similar to a stock dividend. The Rights Offering was oversubscribed and generated $3.3 million in gross proceeds. The issuance costs derived for the Rights Offering were approximately $128,000. As part of the Rights Offering we issued an aggregate of 18,965,516 shares for $0.174 per share. In addition to the above, a portion of additional revenue we were hoping to recognize in the second quarter has become backlogged due to a lack of components, as further described below, and will be delivered later in the year. Therefore, we believe that we have sufficient capital resources to fund our operations for at least the next 12 months. In addition, we engaged an investment bank to explore strategic options and are investing resources in this process.

 

10

 

 

In connection with the outbreak of COVID-19, we have taken steps to protect our workforce in Israel, the United States, Poland, South Africa and elsewhere. Such steps include working from home where possible, minimizing face-to-face meetings, utilizing video conference as much as possible, social distancing at facilities and elimination of most international travel. We continue to comply with all local health directives.

 

We have continued to see an interest from new customers, potential customers and partners as they forecasted that the need for our products will grow, yet execution of closing is still slow due to the current business environment.

 

While interest from current and new customers is growing, which is reflected in an increasing rate of orders, a global shortage in components, which caused an increase in components’ prices, freight cost and longer lead-times, has created a delay in fulfilling customers’ orders, which impacted our revenues and product gross margin, mainly in the Retail segment. As a response to this business environment, we encourage our customers to provide their forecast for their demand and continue to maintain a comprehensive network of worldwide suppliers in order to optimize our access to critical components. In addition, we recently purchased an amount of such components to be used for sales later this year. As long as the COVID-19 pandemic continues, the components’ lead-time may be longer than normal and the shortage in components may continue or get worse.

 

It is difficult to predict what other impacts the COVID-19 pandemic may have on us.

 

Operating activities related to continuing operations 

 

For the six months ended June 30, 2021, net cash used in continuing operating activities was $3.2 million, primarily due to a $4.3 million net loss from continuing operations, a $1.1 million increase in trade receivables, net, a $416,000 increase in other receivables and prepaid expenses, a $263,000 increase in inventories, a $55,000 change in accrued interest and linkage differences and $13,000 of deferred tax benefits, net, partially offset by a $2.0 million loss from change in fair value of embedded derivative, a $544,000 increase in trade payables, $200,000 of depreciation and amortization, a $173,000 increase in other current liabilities, $29,000 of expenses due to stock-based compensation issued to employees and others, $10,000 of transaction expenses related to the convertible short-term loan received from shareholders and a $5,000 change in accrued severance pay, net.

 

For the six months ended June 30, 2020, net cash used in continuing operating activities was $33,000 primarily due to a $1.5 million net loss from continuing operations, a $283,000 decrease in other current liabilities, a $162,000 change in accrued interest and linkage differences and a $92,000 increase in other receivables and prepaid expenses, partially offset by a $1.3 million increase in trade payables, a $380,000 decrease in inventories, $212,000 of depreciation and amortization, a $92,000 decrease in trade receivables, net, $28,000 of expenses due to stock based compensation issued to employees, $17,000 of deferred tax expenses, net, and a $11,000 change in accrued severance pay, net.

 

Operating activities related to discontinued operations

 

For the six months ended June 30, 2021, net cash used in discontinued operating activities was $91,000, mainly related to the Mass Transit Ticketing operation that was managed by ASEC, and legal expenses related to the dispute with Merwell Inc. and SuperCom Ltd. in connection with the SmartID division.

 

For the six months ended June 30, 2020, net cash used in discontinued operating activities was $1.3 million, mainly related to the Mass Transit Ticketing operation that was managed by ASEC and to expenses derived from legal proceedings with Harel Insurance Company Ltd.

 

11

 

 

Investing and financing activities related to continuing operations

 

For the six months ended June 30, 2021, net cash used in continuing investing activities was $1.6 million, mainly due to a $1.5 million change in short-term investments, and $137,000 of purchases of property and equipment and intangible assets.

 

For the six months ended June 30, 2020, net cash provided by continuing investing activities was $228,000, mainly due to a $511,000 change in short-term investments, net, partially offset by $283,000 of purchases of property and equipment and intangible assets.

 

For the six months ended June 30, 2021, net cash provided by continuing financing activities was $2.7 million, mainly due to $3.2 million in proceeds from issuance of shares as a result of the Rights Offering, net of issuance costs and a $923,000 convertible short-term loan received from shareholders, net of transaction expenses, partially offset by a $1.5 million decrease in short-term bank credit and loans, net, and a $2,000 repayment of long-term bank loans.

 

For the six months ended June 30, 2020, net cash provided by continuing financing activities was $1.4 million, mainly due to $1.4 million of proceeds from issuance of shares, net of issuance costs, and a $62,000 increase in short-term bank credit and loans, net, partially offset by a $7,000 of repayment of long-term bank loans.

 

Investing and financing activities related to discontinued operations

 

For the six months ended June 30, 2021, net cash provided by discontinued investing activities was $1.3 million, mainly related to $2.7 million consideration for the sale of ASEC, partially offset by cash and cash equivalents as held by ASEC at the closing date of its sale.

 

For the six months ended June 30, 2020, net cash used in discontinued investing activities was $207,000, related to the purchase of long-lived assets for the Mass Transit Ticketing operations.

 

For the six months ended June 30, 2021, net cash used in discontinued financing activities was $380,000, related to repayment of short-term bank loan, for the Mass Transit Ticketing operations.

 

For the six months ended June 30, 2020, net cash provided by discontinued financing activities was $799,000, related to proceeds from long-term bank loan for the Mass Transit Ticketing operations.

 

Off Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures - Our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, are responsible for establishing and maintaining our disclosure controls and procedures (within the meaning of Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended, or Exchange Act). These controls and procedures are designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information was made known to our management, including our CEO and CFO, by others within the Company, as appropriate to allow timely decisions regarding required disclosure. We evaluated these disclosure controls and procedures under the supervision of our CEO and CFO as of June 30, 2021. Based upon that evaluation, our management, including our CEO and CFO, concluded that our disclosure controls and procedures are effective as of such date.

 

Changes in Internal Control Over Financial Reporting - There has been no change in our internal control over financial reporting during the quarter ended June 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

  

12

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

For information with respect to legal proceedings to be disclosed under this Item, see Note 6A to the consolidated Financial Statements included under Part I Item 1 in this Quarterly Report.

 

Item 1A. Risk Factors.

 

Our business faces many risks, a number of which are described under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Other than as set forth below, there have been no material changes from the risk factors previously disclosed in such Annual Report. The risks described in such Annual Report and below may not be the only risks we face. Other risks of which we are not yet aware, or that we currently believe are not material, may also materially and adversely impact our business operations or financial results. If any of the events or circumstances described in the risk factors contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 or described below occurs, our business, financial condition or results of operations could be adversely impacted and the value of an investment in our securities could decline. Investors and prospective investors should consider the risks described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and below, and the information contained under the caption “Forward-Looking Statements” and elsewhere in this Quarterly Report on Form 10-Q before deciding whether to invest in our securities.

 

We face risks due to a global shortage in the components required for the supply of our products.

 

As part of the different impacts of the COVID 19 pandemic, there currently is a global shortage in the components required for the supply of our products, which has led to an increase in the prices of such components, in freight cost and to a longer lead-times. Such shortage can make it harder for us to be able to fulfill orders made by customers, which might have an impact on our revenues and product gross margin, mainly in the Retail segment. In order to mitigate the risk, we encourage our customers to provide a forecast to their demand and continue to maintain a comprehensive network of worldwide suppliers in order to optimize our access to critical components. In addition, during last few months we have purchased a larger amount of such components to be used for sales later this year. However, these measures may not be sufficient to mitigate the aforementioned risks. As long as the COVID-19 pandemic continues, the components’ lead-time may be longer than normal and shortage in components may continue or become greater which would adversely affect our business.

 

Item 5. Other Information.

 

On July 19, 2021, our Compensation Committee of the Board of Directors, or the Board, approved, and recommended the Board to approve, our new 2021 equity incentive plan, or the Plan. On July 22, 2021, the Board approved the Plan. Following approval of the Plan we ceased issuing securities under our 2001 Stock Option Plan.

 

The Plan provides us with a general guidance as to the grants of equity to employees and service providers (such as the types of equity to be granted, vesting schedules, determination of exercise prices, exercise of options, etc.) as well as containing provisions needed for the compliance with the requirements of the Israeli Tax Authority. The below summary is subject to the full terms of the Plan that is attached to this Quarterly Report on Form 10-Q as Exhibit 10.2.

 

The purpose of the Plan is to increase shareholder value and to advance the interests of the Company by furnishing economic incentives.

 

Administration of the Plan

 

The Plan is administered by the Board or by a committee comprised of some of its members, which shall have the power and authority detailed in the Plan. References to the Board include also such committee. All decisions, determinations and interpretations of the Board shall be final and binding on all grantees. No member of the Board shall be liable towards any grantee for any action taken or determination made in good faith with respect to the Plan or any securities issued thereunder.

 

13

 

 

Designation of Grantees

 

The persons eligible for participation in the Plan as grantees, or Grantees, are any employees and non-employees of the Company and/or of any of the Company’s affiliates and any other person which the Board determines to be eligible for the issuance of awards. Securities under Section 102, or Section 102, of the Israeli Income Tax Ordinance, or ITO, shall be issued only to employees of the Company and/or an affiliate thereof.

 

Shares Subject to the Plan

 

The aggregate number of shares reserved for the purposes of the Plan shall be fixed from time to time by the Board. Currently there are 3.9 million shares reserved for issuance under the Plan. Any shares which at the time of termination of the Plan remain unissued and do not underlie any outstanding options, shall cease to be reserved for the purpose of the Plan. Should any option, or any portion thereof, for any reason expire or be cancelled prior to its exercise, the shares subject to such option shall become available for issuance or sale under the Plan. Shares may be made available from the authorized but unissued shares of the Company or from shares held in the Company’s treasury.

 

With respect to the Restricted Shares (as defined below), the Grantee shall also have, subject to the full vesting of Restricted Shares and the provisions of the Articles of Association of the Company, the right to sell such shares.

 

Issuance of Restricted Shares

 

The Board may issue Shares which shall be subject to certain restrictions, or Restricted Shares, and condition their grant or vesting upon the attainment of specified performance targets or such other factors as the Board may determine.

 

Upon delivery of a notice to the Grantee of non-achievement of the vesting milestones, setting forth the number of Shares to be repurchased or forfeited by the Company, or the Repurchased Shares, the Company shall become the legal and beneficial owner of the Repurchased Shares and all rights and interests therein or thereto without the necessity for any action on the part of the Company or Grantee.

 

Term of Option

 

Each unexercised option granted pursuant to the Plan shall expire upon the tenth anniversary of the date of grant thereof or earlier, in the event of termination of Grantee’s employment or service with the Company or any of its subsidiaries, unless the Board established a shorter or longer term for an option or there are circumstances under which such option shall be cancelled or expire.

 

Exercise Price and Consideration

 

The exercise price shall be determined by the Board in its sole discretion. The proceeds received by the Company from the issuance of Shares and/or Shares subject to options will be added to the general funds of the Company and used at the Company’s discretion.

 

Vesting of the Options

 

Generally, options shall vest and become exercisable according to the following three year vesting schedule, such that one third (1/3) of the options granted shall become vested upon lapse of each year as of the date of grant, or any other date determined by the Board, provided that on and before the respective preceding vesting dates the option holder, or the Optionee, shall be and shall have been continuously employed by the Company or provided services to the Company. The vesting provisions of individual options or Restricted Shares may vary, as the Board may determine.

 

14

 

 

Exercise of Options

 

The exercise of options shall be effective upon receipt of Optionee’s written notice by the Company together with full payment of the exercise price and the execution and delivery of any other required document. The notice of exercise is irrevocable and may not be rescinded or revised once it has been delivered to the Company.

 

Each vested option granted under the Plan shall be exercisable. However, no option shall be exercisable after the expiration date set forth in the grant agreement.

 

The exercise of options may be made through a net exercise mechanism as set forth in the Plan.

 

The options may be exercised by the Optionee in whole at any time or in part from time to time, to the extent that the options become vested and exercisable, prior to the expiration date, and provided that the Optionee is employed by or providing services to the Company or any of its affiliates, at all times during the period beginning with the date of grant and ending upon the date of exercise.

 

Right as a Shareholder

 

Shares and options issued pursuant to the Plan shall be issued in the name of the Grantee or to a trustee, or the Trustee, in the name of the Grantee, as applicable. With respect to options, prior to exercise and until the registration of the Optionee as a holder of Shares in the Company’s register of shareholders, an Optionee, as such, shall have no right to vote or receive dividends or any other rights of or as a shareholder

 

An Optionee shall not have any of the rights or privileges of a shareholder in the Company in respect of any Shares purchasable upon the exercise of any options, until the Optionee shall have exercised the option, paid the exercise price and applicable tax thereof and have been registered as a holder of such Shares in the Company’s register of shareholders upon exercise of the options in accordance with the provisions of the Plan.

 

Termination of Employment

 

In the event of termination other than for cause, as such term is defined in the Plan, all options issued to that Optionee, which are vested and exercisable at the time of such termination, may be exercised within the period specified in the Plan and then will expire. Any Shares covered by the unvested portion of the option shall revert back to the Plan. In the event of termination for cause, all outstanding options granted to such Optionee (whether vested or not) shall, to the extent not theretofore exercised, immediately expire and shall be of no further force and effect as of the date of such termination and shall revert to the Plan.

 

With respect to an unapproved 102 Option, which are options that do not qualify for favorable tax treatment under the ITO, the Optionee shall extend to the Company and/or its affiliate security or guarantee for the payment of tax due at the time of sale of Shares, all in accordance with the provisions of Section 102.

 

Adjustments

 

A Grantee’s rights to purchase or receive Shares under the Plan shall be adjusted in the event of changes in capitalization, such as share split and reverse share split, dissolution or liquidation. In addition, special arrangements will take place in the case of certain transactions, or a Transaction, which is defined as (i) a merger, consolidation, acquisition or reorganization of the Company with one or more other entities in which the Company is not the surviving entity (or if in the context of a reverse triangular merger, the Company is the surviving entity), (ii) an acquisition of all or over 50% of the shares of the Company in a transaction or series of related transactions. For the avoidance of doubt, any merger or reverse triangular merger with a publicly traded entity in which the shareholders of the Company prior to such transaction hold more than 50% of the shares of the combined entity, shall not be considered a Transaction; (iii) a sale and/or transfer (including by way an exclusive license) of all or substantially all of the assets or shares of the Company to a third party(ies); or (iv) such other transaction with a similar effect, as shall be determined by the Board in each case, other than a transaction or series of a related transaction for the sole purpose of effecting a change in domicile of the Company.

 

In the event of a Transaction, all unvested options and Restricted Shares of employees who worked at least one year with the Company shall fully vest immediately prior to the consummation of a Transaction and each outstanding unexercised option and Restricted Share may be assumed by the successor company or an affiliate thereof, or may be replaced by a share option, or a share, as applicable, in, or right against, the successor company or an affiliate thereof, and appropriate adjustments shall be made in the number of shares (and respectively, in the case of options, the exercise price per share) in order to reflect such an assumption or replacement. If the options and/or the Restricted Share are not assumed or substituted, the Board may decide that the vesting periods set forth in the grant agreements shall be fully or partially accelerated.

 

15

 

 

In connection with a Transaction, the Board may also determine that all options and Restricted Shares which are “in the money” with respect to the Transaction, shall be replaced with the right of the Optionee to receive the difference between the per-share consideration being paid in the Transaction for each Share, and the exercise price, minus the amount of any applicable withholding taxes, and all options and/or Restricted Shares which are not “in the money” may, at the full discretion of the Board, be cancelled or assumed as aforesaid. In addition, the Board may decide that the Optionees shall be subject to all or some of the same terms and conditions, and risks, as the risks being taken by the Company’s shareholders in the Transaction, pro rata and mutatis mutandis.

 

Designation of Shares and/or Options Pursuant to Section 102

 

The Board may designate Shares and/or options to qualify under Section 102 under the capital gains route or ordinary income route.. Such election shall be filed with the Israeli Tax Authority, and shall obligate the Company to issue only one type of approved 102 Shares, or Approved 102 Shares, and/or approved 102 Options, or Approved 102 Options, it has elected.

 

Trustee

 

Any Approved 102 Shares and/or Approved 102 Options shall be issued pursuant to the Plan to a Trustee who shall hold them in trust pursuant to the Company’s instructions from time to time.

 

Dividends

 

With respect to all Shares issued, the Grantee (or the Trustee of his behalf, in the case of 102 Shares or Shares issued upon the exercise of 102 Options) shall be entitled to receive dividends in accordance with the quantity of such Shares, subject to the provisions of the Company’s Articles of Association and subject to any applicable taxation on distribution of dividends, and, when applicable, subject to the provisions of Section 102.

 

Amendment and Termination of the Plan

 

The Board may terminate, alter, adjust, suspend or amend the Plan, or any part thereof, in any respect, except that if at any time the approval of the shareholders of the Company is required pursuant to the Israeli Companies Law, 1999 or the regulations promulgated thereunder, the Board may not effect such modification or amendment without such approval.

 

Governing Law

 

The validity, construction, interpretation, administration and effect of the Plan and any rules, regulations and actions relating to the Plan will be governed by and construed exclusively in accordance with the laws of the State of Israel, notwithstanding the conflicts of laws principles of any jurisdiction. The competent courts in Tel Aviv shall have sole and exclusive jurisdiction over any dispute with regard to any controversy or claim arising under, out of, or in connection with this Plan, its validity, its interpretation, its execution or any breach or claimed breach thereof.

 

Item 6. Exhibits.

 

3.1

Amended and Restated Articles of Incorporation, as amended on April 14, 2020 (incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 12, 2020).

   
3.2

Memorandum of Association, as amended and restated after the April 14, 2020 amendment (incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 12, 2020).

   
10.1

Notice of Exercise of Option and Agreement dated June 17, 2021 (incorporated by reference to the Company’s Current Report on Form 8-K filed on June 23, 2021).

   
10.2* On Track Innovations Ltd. 2021 Equity Incentive Plan.
   

31.1*

Rule 13a-14(a) Certification of Chief Executive Officer.
   
31.2* Rule 13a-14(a) Certification of Chief Financial Officer.
   
32.1** Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.
   
32.2**   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.
   
101 * The following materials from our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 formatted in XBRL (eXtensible Business Reporting Language): (i) the Interim Condensed Consolidated Balance Sheets, (ii) the Interim Condensed Consolidated Statements of Operations, (iii) the Interim Condensed Consolidated Statements of Comprehensive Loss, (iv) the Interim Condensed Statements of Changes in Equity, (v) the Interim Condensed Consolidated Statements of Cash Flows, and (vi) the Notes to Interim Condensed Consolidated Financial Statements, tagged as blocks of text and in detail.
   
104* Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

* Filed herewith.

** Furnished herewith.

 

16

 

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  

ON TRACK INNOVATIONS LTD.

        

By: /s/ Yehuda Holtzman  
  Yehuda Holtzman, Chief Executive Officer  
  (Principal Executive Officer)  
   
Dated: August 16, 2021  

 

By: /s/ Assaf Cohen  
  Assaf Cohen, Chief Financial Officer  
  (Principal Financial and Accounting Officer)  
   
Dated: August 16, 2021  

 

17

 

00-0000000 Including $7 that derives from discontinued operations. Derives from discontinued operations. Including cash and cash equivalents from discontinued operations held for sale. See also Note 8. See Note 6A(2). This amount is recorded as loss from change in fair value of embedded derivative as part of the financial expenses in the statements of operations of the first quarter of 2021. Mainly including net loss of $177 due to the legal proceedings, as mentioned in Note 6A(2), and loss of $746 due to transfer of the exchange differences on translation, as derived from ASEC, from other comprehensive loss to the statement of operations loss (see statements of comprehensive loss). Those liabilities were received for a long-term (more than twelve months) in ASEC, but were presented as held for sale within the current assets as of December 31, 2020, because the Company has determined that the sale of ASEC qualified as held for sale and as a discontinued operation as of December 31, 2020. Gross profit as reviewed by the CODM, represents gross profit, adjusted to exclude depreciation and stock-based compensation. false 972 --12-31 Q2 0001021604 6868000 0001021604 2021-01-01 2021-06-30 0001021604 2021-08-09 0001021604 2021-06-30 0001021604 2020-12-31 0001021604 2021-04-01 2021-06-30 0001021604 2020-04-01 2020-06-30 0001021604 2020-01-01 2020-06-30 0001021604 us-gaap:CommonStockMember 2020-03-31 0001021604 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001021604 us-gaap:TreasuryStockMember 2020-03-31 0001021604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001021604 us-gaap:RetainedEarningsMember 2020-03-31 0001021604 2020-03-31 0001021604 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001021604 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001021604 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0001021604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001021604 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001021604 us-gaap:CommonStockMember 2020-06-30 0001021604 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001021604 us-gaap:TreasuryStockMember 2020-06-30 0001021604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001021604 us-gaap:RetainedEarningsMember 2020-06-30 0001021604 2020-06-30 0001021604 us-gaap:CommonStockMember 2021-03-31 0001021604 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001021604 us-gaap:TreasuryStockMember 2021-03-31 0001021604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001021604 us-gaap:RetainedEarningsMember 2021-03-31 0001021604 2021-03-31 0001021604 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001021604 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001021604 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0001021604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001021604 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001021604 us-gaap:CommonStockMember 2021-06-30 0001021604 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001021604 us-gaap:TreasuryStockMember 2021-06-30 0001021604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001021604 us-gaap:RetainedEarningsMember 2021-06-30 0001021604 us-gaap:CommonStockMember 2019-12-31 0001021604 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001021604 us-gaap:TreasuryStockMember 2019-12-31 0001021604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001021604 us-gaap:RetainedEarningsMember 2019-12-31 0001021604 2019-12-31 0001021604 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001021604 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001021604 us-gaap:TreasuryStockMember 2020-01-01 2020-06-30 0001021604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-06-30 0001021604 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001021604 us-gaap:CommonStockMember 2020-12-31 0001021604 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001021604 us-gaap:TreasuryStockMember 2020-12-31 0001021604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001021604 us-gaap:RetainedEarningsMember 2020-12-31 0001021604 us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001021604 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-06-30 0001021604 us-gaap:TreasuryStockMember 2021-01-01 2021-06-30 0001021604 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-06-30 0001021604 us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001021604 2013-12-02 2013-12-13 0001021604 2016-04-05 2016-04-20 0001021604 2021-03-05 2021-03-29 0001021604 2021-04-02 2021-04-30 0001021604 otiv:LoanAgreementMember 2020-12-09 0001021604 otiv:OneTranchesMember 2020-12-01 2020-12-09 0001021604 otiv:LoanAgreementMember 2020-12-01 2020-12-17 0001021604 2021-02-24 2021-03-02 0001021604 2021-06-01 2021-06-17 0001021604 2020-12-01 2020-12-17 0001021604 2021-02-25 2021-03-02 0001021604 2020-12-17 0001021604 2021-01-01 2021-01-28 0001021604 2021-01-28 0001021604 2021-01-25 2021-03-02 0001021604 2021-03-02 0001021604 otiv:ConversionComponentMember 2021-03-31 0001021604 otiv:LoanComponentMember 2021-03-31 0001021604 otiv:ConversionComponentMember 2021-06-30 0001021604 otiv:ConversionComponentMember 2021-01-01 2021-06-30 0001021604 2021-03-03 2021-06-30 0001021604 otiv:MerwellIncMember 2016-02-02 2016-02-21 0001021604 2019-01-08 0001021604 2019-06-06 2019-06-12 0001021604 srt:MinimumMember 2020-09-01 2020-09-16 0001021604 srt:MaximumMember 2020-09-01 2020-09-16 0001021604 2021-08-01 2021-08-31 0001021604 2013-10-03 2013-10-03 0001021604 srt:MinimumMember us-gaap:ResearchAndDevelopmentArrangementMember 2021-06-30 0001021604 srt:MaximumMember us-gaap:ResearchAndDevelopmentArrangementMember 2021-06-30 0001021604 us-gaap:ResearchAndDevelopmentArrangementMember 2021-01-01 2021-06-30 0001021604 otiv:RetailAndMassTransitTicketingMember 2021-04-01 2021-06-30 0001021604 us-gaap:PublicUtilitiesInventoryPetroleumProductsMember 2021-04-01 2021-06-30 0001021604 otiv:RetailAndMassTransitTicketingMember 2020-04-01 2020-06-30 0001021604 us-gaap:PublicUtilitiesInventoryPetroleumProductsMember 2020-04-01 2020-06-30 0001021604 otiv:RetailAndMassTransitTicketingMember 2021-01-01 2021-06-30 0001021604 us-gaap:PublicUtilitiesInventoryPetroleumProductsMember 2021-01-01 2021-06-30 0001021604 otiv:RetailAndMassTransitTicketingMember 2020-01-01 2020-06-30 0001021604 us-gaap:PublicUtilitiesInventoryPetroleumProductsMember 2020-01-01 2020-06-30 0001021604 us-gaap:PrivatePlacementMember 2019-12-23 0001021604 2019-12-23 0001021604 2020-01-31 0001021604 2019-12-01 2019-12-31 0001021604 2020-01-02 2020-01-31 0001021604 2020-01-01 2020-03-31 0001021604 2019-01-01 2019-12-31 0001021604 otiv:RightsOfferingMember 2021-05-19 0001021604 otiv:RightsOfferingMember 2021-01-01 2021-06-30 0001021604 us-gaap:EmployeeStockOptionMember 2021-06-30 0001021604 us-gaap:EmployeeStockOptionMember 2020-06-30 0001021604 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001021604 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001021604 us-gaap:EmployeeStockOptionMember 2020-12-31 0001021604 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001021604 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001021604 2020-01-01 2020-12-31 0001021604 srt:MinimumMember 2021-01-01 2021-06-30 0001021604 srt:MinimumMember 2020-01-01 2020-06-30 0001021604 otiv:ExcercisePriceRangeOneMember 2021-06-30 0001021604 otiv:ExcercisePriceRangeOneMember 2021-01-01 2021-06-30 0001021604 otiv:ExcercisePriceRangeTwoMember 2021-06-30 0001021604 otiv:ExcercisePriceRangeTwoMember 2021-01-01 2021-06-30 0001021604 us-gaap:RetailMember 2021-04-01 2021-06-30 0001021604 otiv:PetroleumMember 2021-04-01 2021-06-30 0001021604 us-gaap:RetailMember 2020-04-01 2020-06-30 0001021604 otiv:PetroleumMember 2020-04-01 2020-06-30 0001021604 us-gaap:RetailMember 2021-01-01 2021-06-30 0001021604 otiv:PetroleumMember 2021-01-01 2021-06-30 0001021604 us-gaap:RetailMember 2020-01-01 2020-06-30 0001021604 otiv:PetroleumMember 2020-01-01 2020-06-30 0001021604 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-07-23 xbrli:shares iso4217:USD iso4217:ILS xbrli:shares iso4217:USD xbrli:shares xbrli:pure

Exhibit 10.2

 

ON TRACK INNOVATIONS LTD.

 

2021 INCENTIVE EQUITY PLAN

 

This plan, as amended from time to time, shall be known as the On Track Innovations Ltd. 2021 Incentive Equity Plan (the “Plan”).

 

1. Purpose

 

The Plan is intended to increase shareholder value and to advance the interests of the Company by furnishing economic incentives designed (i) to provide an incentive to attract, motivate, and retain, in the employ of the Company and its Affiliates (as defined below), persons of training, experience, and ability, (ii) to attract employees, directors, office holders, consultants, service providers and others who can provide services which are considered valuable from the perspective of the Company, to encourage the sense of proprietorship of such persons and, (iii) to stimulate the active interest of such persons in the development and financial success of the Company by providing them with Awards, pursuant to the Plan.

 

2. Definitions

 

For purposes of interpreting the Plan and related documents, the following definitions shall apply:

 

(a) Affiliate” – means an entity controlling, controlled by or under common control with a Person. For the purpose of this definition of Affiliate, “control” shall mean the direct or indirect (whether alone or together with a “relative,” as defined in Section 76(d) of the Tax Ordinance) holding of, or right to hold or to acquire, 10% or more of the issued share capital and/or voting rights, the right to receive 10% or more of the profits and/or the right to appoint a director.

 

(b) Applicable Laws” – means the laws, regulations and orders of the State of Israel, as well as requirements relating to the administration of employee share and/or option plans under any stock exchange or quotation system on which the Shares are then listed or quoted.

 

(c) Approved 102 Option” – means an Option issued pursuant to Section 102(b) of the Tax Ordinance and held in trust by the Trustee for the benefit of the Optionee.

 

(d) Approved 102 Shares” – means a Share (including Restricted Share) issued pursuant to Section 102(b) of the Tax Ordinance and held in trust by the Trustee for the benefit of the Grantee.

 

(e) Award” – shall include Options, Shares and/or Restricted Shares granted under and governed by the provisions of the Plan.

 

(f) Board” – means the Board of Directors of the Company.

 

(g) Cause” – means (i) a conviction of any felony involving moral turpitude or affecting the Company; (ii) any refusal, or a failure (as a result of gross negligence or willful misconduct), to carry out a reasonable directive of the management of the Company or any of its Affiliates, or as applicable, the Board, which was within the scope of the duties of the Grantee and which involves the business of the Company or any of its Affiliates and which was capable of being lawfully performed by the Grantee; (iii) an embezzlement or theft of funds of the Company or any of its Affiliates; (iv) a breach of a Grantee’s fiduciary duties or breach in bad faith of Grantee’s duties of care towards the Company or any of its Affiliates; including, without limitation, self-dealing, prohibited disclosure of confidential information of, or relating to, the Company or any of its Affiliates, or engagement in any business competitive to the business of the Company or of its Affiliates; (v) conduct (other than conduct which is clearly carried out in good faith) which is reasonably determined by the Board to be materially detrimental to the Company; (vi) any other cause justifying termination or dismissal without severance payment under applicable law; and (vii) any other event defined as “Cause” under a Grantee’s employment or engagement agreement with the Company or its any of its Affiliates.

 

 

 

 

(h) Chairman” – means the chairman of the Board.

 

(i) Company” – means On Track Innovations Ltd., an Israeli public company, bearing registration number 52-0042862 and any Successor Company.

 

(j) Controlling Shareholder” – shall have the meaning ascribed to it in Section 32(9) of the Tax Ordinance.

 

(k) Date of Grant” – shall have the meaning set forth in section 21 below.

 

(l) Director” – means a member of the Board.

 

(m) “Disability” – means a Grantee’s inability to perform his or her duties towards the Company or its applicable Affiliate, for a consecutive period of at least 180 days or for an aggregate period of 180 days in any 360 days period, by reason of any medically determinable physical or mental impairment, as determined by a physician selected by the Grantee and acceptable to the Company.

 

(n) Employee” – means an individual who is employed by the Company or any of its Affiliates, including an individual who is serving as a Director or an Office Holder, of the Company or any of its Affiliates, but excluding a Controlling Shareholder on the Date of Grant of Shares and/or Option under the Plan or as a result of the applicable grant of Shares and/or the exercise of the Option.

 

(o) Employment” – means (i) in case of an Employee, salaried employment with the Company or any Affiliate of the Company, which shall include (unless the Board shall otherwise determine, in its full discretion) any period of vacation, any approved leave of absence or any salary continuation or severance pay period and, at the discretion of the Board, may include service with any former Affiliate of the Company; (ii) in case of Director or Office Holder (who is not an Employee), such person’s engagement with the Company or any Affiliate of the Company in the provision of services as a Director and/or Office Holder, as applicable.

 

(p) End of the Period” – shall have the meaning defined under Section 102.

 

(q) Exercise Price” – shall mean the average closing price of the Shares during the last thirty (30) days prior to the date of grant, to be paid in order to purchase a Share in connection with the exercise of an Option, unless determined otherwise by the Board.

 

(r) Expiration Date” – with respect to an Option, shall mean the date that such Option is no longer exercisable, as set forth in Section 7.

 

-2-

 

 

(s) Fair Market Value” – means, as of any date, the value of a Share determined as follows:

 

(i) If the Shares are listed on any established stock exchange or a national market system, including without limitation the TASE, the NASDAQ National Market, the AIM market of the London Stock Exchange or The NASDAQ SmallCap Market of The NASDAQ Stock Market, the Fair Market Value of the Shares shall be the average closing sales price for such Shares (or the closing bid, if no sales were reported) as quoted on such exchange or system for a period determined by the Board, in its sole discretion, prior to the time of determination; provided that the Board may fix the “Fair Market Value” of the Shares in another reasonable manner, if so requested by an acquirer of all or substantially all of the Company’s shares or assets;

 

(ii) If the Shares are regularly quoted on an automated quotation system (including the OTC Bulletin Board) or by a recognized securities dealer, its Fair Market Value shall be the closing sales price for such Share as quoted on such system or by such securities dealer on the date of determination, but if selling prices are not reported, their Fair Market Value shall be difference between the high bid and low asked prices for the Shares on the last market trading day prior to the day of determination (or, if no such prices were reported on that date, on the last date such prices were reported), as reported in a source the Committee deems reliable, provided that the Board may fix the “Fair Market Value” of the Shares in another reasonable manner, if so requested by an acquirer of all or substantially all of the Company’s shares or assets; or

 

(iii) In the absence of an established market for the Shares, the Fair Market Value thereof shall be determined by the Board.

 

(iv) Without derogating from the above, solely for the purpose of determining the tax liability pursuant to Section 102(b)(3) of the Tax Ordinance, if at the Date of Grant the Company’s shares are listed on any established stock exchange or a national market system or if the Company’s shares will be registered for trading within ninety (90) days following the Date of Grant, the Fair Market Value of a Share at the Date of Grant shall be determined in accordance with the average value of the Company’s shares on the thirty (30) trading days preceding the Date of Grant or on the thirty (30) trading days following the date of registration for trading, as the case may be.

 

(t) Grant Agreement” – means a written or electronic agreement between the Company and a Grantee evidencing the terms and conditions of the issuance of Shares or a grant of an Option. The Grant Agreement shall state, inter alia and as applicable, the number of Shares being issued (or the number of shares underlying the Option being granted), the dates when the Option may be exercised, in whole or in part (subject to Section 9 of the Plan), the Exercise Price subject to the Option and such other terms as the Board in its discretion may prescribe. The Grant Agreement is subject to the terms and conditions of the Plan. Grant Agreements may vary among different Grantees, as determined by the Board in its sole discretion.

 

(u) Grantee” – means a party to whom Shares are issued under the Plan or an Optionee.

 

(v) Office Holder” – shall have the meaning defined under the Israeli Companies Law – 1999.

 

-3-

 

 

(w) Option” – means the right to purchase the number of Shares specified by the Board, at a price and for the term fixed by the Board in accordance with the Plan and subject to any other limitations and restrictions as the Plan and the Board shall impose.

 

(x) Optionee” – means any Person who receives or holds an Option under the Plan.

 

(y) Person” – includes both individuals and corporate entities.

 

(z) Restricted Share” – means the issuance of Shares subject to certain restrictions, in accordance with Section 6 of the Plan and as defined therein.

 

(aa) Section 102” – means Section 102 of the Tax Ordinance and any regulations, rules, orders or other legislative item promulgated thereunder as now in effect or as hereafter enacted or amended.

 

(bb) “Securities Laws” – means the Israeli Securities Law, 1968, as amended, the U.S. Securities Act of 1933, as amended, or any similar law of any other jurisdiction, and the rules and regulations promulgated thereunder.

 

(cc) Share” – means the ordinary shares, nominal value NIS 0.1 per share, of the Company, as may be adjusted pursuant to Section 13 of the Plan.

 

(dd) Successor Company” – means (i) any entity into and with which the Company is merged or consolidated pursuant to a Transaction; and (ii) an entity which acquires all or substantially all of the assets or shares of the Company.

 

(ee) TASE” – means the Tel Aviv Stock Exchange.

 

(ff) Tax Ordinance” – means the Israeli Income Tax Ordinance [New Version]-1961 and any regulations, rules, orders or other legislative item promulgated thereunder as now in effect or as hereafter enacted or amended.

 

(gg) Transaction” – means (i) a merger, consolidation, acquisition or reorganization of the Company with one or more other entities in which the Company is not the surviving entity (or if in the context of a reverse triangular merger, the Company is the surviving entity), (ii) an acquisition of all or over 50% of the shares of the Company in a transaction or series of related transactions. For the avoidance of doubt, any merger or reverse triangular merger with a publicly traded entity in which the shareholders of the Company prior to such transaction hold more than 50% of the shares of the combined entity, shall not be considered a Transaction; (iii) a sale and/or transfer (including by way an exclusive license) of all or substantially all of the assets or shares of the Company to a third party(ies); (iv) such other transaction with a similar effect, as shall be determined by the Board in each case, other than a transaction or series of a related transaction for the sole purpose of effecting a change in domicile of the Company.

 

(hh) Trustee” – means any Person or entity who complies with the terms set forth in Section 3(a)(1) and/or (2) of the Israeli Income Tax Rules (Tax Relief for Allocation of Shares to Employees) 2003 and is appointed by the Company and approved by the Assessing Officer to serve as a trustee for Approved 102 Shares and/or for Approved 102 Options.

 

(ii) Trust Agreement” – means a trust agreement between the Company and the Trustee with respect to Approved 102 Shares and/or Approved 102 Options issued under the Plan, substantially in the form of Addendum B to the Israeli Income Tax Rules (Tax Relief for Allocation of Shares to Employees) 2003, as now in effect or as hereafter amended.

 

-4-

 

 

(jj) Vesting Dates” – means, (i) with respect to any Option, the date as of which the Optionee shall be entitled to exercise such Option, as set forth in Section 9 of the Plan and in the Grant Agreement; and (ii) with respect to Restricted Shares, the date following which the Company does not have a right to repurchase or forfeit such Restricted Shares, as set forth in Section 6 of the Plan and in the Grant Agreement.

 

(kk) Unapproved 102 Option” – means an Option issued pursuant to Section 102(c) of the Tax Ordinance and not held in trust by a Trustee.

 

(ll) Unapproved 102 Share” – means a Share (including Restricted Share) issued pursuant to Section 102(c) of the Tax Ordinance and not held in trust by a Trustee.

 

(mm) 102 Option” and “102 Share” – means an Option or Share (including Restricted Shares) which is subject to the provisions of Section 102.

 

(nn) CGO” – means Approved 102 Options and/or Approved 102 Shares which are intended (subject to the Approved 102 Options and/or Approved 102 Shares being held by the Trustee until the End of the Period) to be subject to tax treatment in accordance with the provisions of Section 102(b)(2) or 102(b)(3), as applicable, of the Tax Ordinance, in accordance with the Company’s decision to use the capital gains track of Section 102.

 

(oo) OIO” – means Approved 102 Options and/or Approved 102 Shares which are intended by the Company to qualify under the ordinary income tax treatment in accordance with the provisions of Section 102(b)(1) of the Tax Ordinance, in accordance with the Company’s decision to use the employment income track of Section 102.

 

(pp) 3(i) Options” – means Options that are not subject to taxation under Section 102. Such options are available for issuance to non-Employees selected by the Board.

 

3. Administration of the Plan

 

(a) The Plan shall be administered by the Board; provided, that the Board may appoint a committee which shall be comprised of some of its members (no fewer than two members of the Board), such as the Company’s Compensation Committee, in order to administer the Plan. In such case, all references in this Plan to “the Board” shall be deemed references to such committee, subject to the provisions of the Companies Law, 1999. The Board shall have the authority in its sole discretion, subject to applicable law, to administer the Plan and to exercise all the powers and authorities specifically granted to it under the Plan as necessary and advisable in the administration of the Plan.

 

(b) To the extent permitted under applicable law, the Board shall have the full power and authority to: (i) designate Grantees; (ii) determine the terms and provisions of the respective Grant Agreements (which need not be identical), including and if applicable, but not limited to, the number of Awards to be issued or granted to each Grantee, the number of Shares underlying an Option, provisions concerning the time and extent to which Options may be exercised, and the nature and duration of restrictions as to the transferability or restrictions constituting a substantial risk of forfeiture and to cancel or suspend Awards, as necessary; (iii) if applicable, determine the Fair Market Value of the Shares covered by each Option; (iv) make an election as to the Awards (CGT or IOI) and designate the type of Shares and/or Options.

 

-5-

 

 

(c) Subject to the provisions of the Plan, the Applicable Laws and Section 102, the Board shall have the authority, in its discretion:

 

(i) to construe and interpret the terms of the Plan and any Grant Agreements pursuant to the Plan;

 

(ii) to designate the Employees and non-Employees to whom Awards may from time to time be granted or issued hereunder;

 

(iii) to determine the number of Shares to be issued, or covered by each Awards granted, under the Plan;

 

(iv) to prescribe forms of Grant Agreement for use under the Plan;

 

(v) to determine Vesting Dates and/or any other performance conditions for the vesting of Awards;

 

(vi) to accelerate and extend certain exercise periods prescribed under this Plan (if applicable);

 

(vii) to determine the terms of any Grant Agreement;

 

(viii) to determine the Exercise Price of any Option issued hereunder;

 

(ix) if applicable, to determine the Fair Market Value of Shares;

 

(x) alter any restrictions and conditions of any Awards;

 

(xi) to prescribe, amend and rescind any rules and regulations relating to the Plan;

 

(xii) correct and reconcile any inconsistency in the Plan or in any agreement relating thereto in a manner and to the extent it shall deem necessary to effectuate the purpose and intent of the Plan; and

 

(xiii) to take all other actions and make all other determinations necessary for the supervision and administration of the Plan.

 

(d) No member of the Board be liable towards any Grantee for any action taken or determination made in good faith with respect to the Plan or any Shares and/or Option issued hereunder.

 

(e) Members of the Board may receive Shares and/or Options under the Plan while serving on the Board.

 

(f) All decisions, determinations and interpretations of the Board shall be final and binding on all Grantees.

 

(g) The Board shall have the authority to grant, at its discretion, to the holder of an outstanding Option, in exchange for the surrender and cancellation of such Option, a new Option having a purchase price equal to, lower than or higher than the Exercise Price of the original Option so surrendered and cancelled and containing such other terms and conditions, or to change the Exercise Price as the Board may prescribe in accordance with the provisions of the Plan.

 

4. Designation of Grantees

 

(a) The Board shall have the authority to issue and grant Awards to Grantees under the Plan.

 

(b) Shares and Options issued under this Plan shall, as applicable, be Unapproved 102 Shares, Restricted Shares, CGO, OIO, Unapproved 102 Options or 3(i) Options.

 

-6-

 

 

(c) Each Share and/or Option issued pursuant to the Plan shall be evidenced by a Grant Agreement, in such form as the Board shall from time to time approve. Each Grant Agreement shall state, among other matters and if applicable, the number of Shares granted or Shares to which an Option relates, the nature of the Award issued thereunder (whether Restricted Shares, CGO, OIO, Unapproved 102 Share, Unapproved 102 Option or a 3(i) Option), the Vesting Dates or vesting schedule, the Exercise Price, the Expiration Date and such other terms and conditions as the Board in its discretion may prescribe, provided that they are consistent with this Plan. The Grant Agreement shall be delivered to the Grantee and shall incorporate the terms of the Plan by reference and specify the terms and conditions thereof and any rules applicable thereto. The Grant Agreement shall be executed by the Grantee and the Company.

 

(d) The Persons eligible for participation in the Plan as Grantees (but they shall only participate in the Plan if the Board decides that they shall so participate) shall include any Employees and non-Employees (such as service providers, consultants and contractors in their personal capacity) of the Company and/or of any of the Company’s Affiliates thereof and any other Person which the Board determines to be eligible for the issuance of Awards; provided, however, that 102 Shares and 102 Options shall be issued only to Employees of the Company and/or an Affiliate thereof, and provided further, that if services have not commenced on the Date of Grant, the grant will be deemed effective upon commencement of actual employment.

 

(e) Neither this Plan nor any Grant Agreement nor any offer of Shares and/or Options to an Grantee shall impose any obligation on the Company or any Affiliate to continue to employ or to engage the services of any Grantee, and nothing in the Plan or in any Grant Agreement issued pursuant thereto shall give any Grantee any right to continue its employment or service to the Company or any Affiliate or restrict the right of the Company or any Affiliate to terminate such employment or services at any time.

 

(f) The issuance of Awards to a Grantee hereunder, shall neither entitle such Grantee to participate, nor disqualify him from participating, in any other issuance of Shares and/or Options pursuant to this Plan or any other share incentive or plan of the Company or any of its Affiliates.

 

(g) The Options and underlying Shares are extraordinary, one-time benefits granted to the Grantees, and are not and shall not be deemed a salary component for any purpose whatsoever, including in connection with calculating severance compensation under Applicable Law.

 

(h) Notwithstanding anything to the contrary, all issuances of Shares and/or Options to Directors and other Office Holders of the Company shall be authorized and implemented in accordance with the provisions of Chapter 5 of Section 6 of the Israeli Companies Law – 1999, or any successor act or regulation, as in effect from time to time.

 

(i) It is acknowledged and agreed that the Company provides no representation and the Grantee is not being guaranteed in any way that an Approved 102 Share or a CGO will be subject to capital gains taxation. If an Award which is intended to qualify for capital gains taxation as an Approved 102 Share or a CGO, does not so qualify, for any reason, including, without limitation, due to gross negligence of the Company or the Trustee, the Grantee shall not have any claims against (i) the Company, (ii) any Affiliate of the Company, (iii) any shareholder of the Company or an Affiliate thereof, (iv) any director or other Office Holder of the Company or any Affiliate thereof, and/or (v) the Trustee.

 

-7-

 

 

5. Shares Subject to the Plan

 

(a) The total number of Shares reserved for the purposes of the Plan (including Shares which may underlie Options) shall be fixed from time to time by the Board, which may increase or decrease the number of shares, on one or numerous occasions, at its sole discretion, and such number shall be subject to adjustment as set forth in Section 13 below. Any Shares which - at the time of termination of the Plan – remain unissued and do not underlie any outstanding Options, shall cease to be reserved for the purpose of the Plan. Should any Option, or any portion thereof, for any reason expire or be cancelled prior to its exercise (including, without limitation, as a result of cessation of Employment or engagement), the Shares subject to such Option (or such expired or cancelled portion of the Option) shall become available for issuance or sale under the Plan.

 

(b) Shares may be made available from the authorized but unissued shares of the Company or from Shares held in the Company’s treasury.

 

(c) Each Share shall be subject to such terms and conditions consistent with the Plan and set forth in the applicable Grant Agreement as the Board may impose from time to time, including, without limitation, restrictions on the sale or other disposition of such Shares, the vesting dates with respect to such Shares, and the right of the Company to reacquire unvested Shares or to forfeit or convert such unvested Shares into dormant shares, at the discretion of the Board, upon termination of the Grantee’s employment or engagement within specified periods or upon the occurrence of such other events as specified in the Grant Agreement. Except as otherwise provided herein and as otherwise determined by the Board and set forth in the Grant Agreement the Grantees shall have all of the rights of a holder of Shares, including the right to receive dividends and to vote the Shares covered thereby (subject to the provisions of Section 15(g)).

 

6. Issuance of Restricted Shares.

 

(a) Notwithstanding anything to the contrary contained herein, the Board may, in its sole discretion, issue Shares directly (i.e., not by way of exercise of an Option) pursuant to this Plan, which Shares, shall be subject to certain restrictions as set forth in this Section ‎6 and in the Grantee’s Grant Agreement (“Restricted Shares”).

 

(b) Eligibility. The Board shall determine the eligible Grantees to whom, and the time or times at which, grants of Shares will be made, the number of Restricted Shares to be awarded, the purchase price (if any) to be paid by the Grantee (subject to subsection (c)), the time or times at which such Restricted Shares may be subject to repurchase or forfeiture (if any) by the Company, the vesting schedule (if any) and rights to acceleration thereof, and such other terms and conditions with respect to the issuance of the Restricted Shares, as the Board shall deem fit. The Board may condition the grant or vesting of the Restricted Shares upon the attainment of specified performance targets or such other factors as the Board may determine, in its sole discretion. In the event that the Grantee’s engagement is terminated for Cause, or Grantee is otherwise not in compliance with the terms and conditions of this Plan or Grant Agreement with respect to the Restricted Shares’ vesting schedule, vesting performance objectives or such other vesting factors as shall be determined in such Grantee’s Grant Agreement, the Board may determine, in its sole discretion, that the Restricted Shares shall be repurchased (with or without consideration) or forfeited by the Company.

 

-8-

 

 

(c) Terms. The purchase price of Restricted Shares shall be determined by the Board but shall not be less than as permitted under applicable law. Restricted Shares must be accepted within a period of 21 days (or such other period as the Board may specify at grant) after the Date of Grant, by executing a Grant Agreement and by paying whatever price (if any) the Board has designated thereunder.

 

(d) Custody. The Board may require that any share certificates evidencing such Restricted Shares be held in custody by the Company or any third party determined by the Company, until the restrictions thereon shall have lapsed, and that, as a condition of any issuance of Restricted Shares, the Grantee shall have delivered a duly signed share transfer deed, endorsed in blank, relating to the Restricted Shares to be issued.

 

(e) Rights as Shareholder. Subject to the provisions of this Plan and as otherwise determined by the Board and set forth in the Grant Agreement, the Grantee shall have, with respect to the Restricted Shares, all of the rights of a holder of Shares including, without limitation, the right to receive any dividends, the right to vote such shares and, subject to and conditioned upon the full vesting of Restricted Shares and the provisions of the Articles of Association of the Company (as in effect from time to time), the right to tender such shares.

 

(f) Mechanics of Repurchase/Forfeiture.

 

i. Upon delivery of a notice to the Grantee of non-achievement of the vesting milestones (including without limitation, any notice referring to termination of employment or services), setting forth the number of Shares to be repurchased or forefeited by the Company (the “Repurchased Shares”), the Company shall become the legal and beneficial owner of the Repurchased Shares and all rights and interests therein or thereto without the necessity for any action on the part of the Company or Grantee, and the Company shall have the right, and the Grantee, by signing the Grant Agreement, hereby appoints the Company and/or the Trustee, as the case may be, as his/her attorney-in-fact and agent and grants an irrevocable power of attorney and proxy to the Company (which may itself appoint an agent to act for it in this context), to (i) retain and transfer to its own name the number of Repurchased Shares being repurchased or forfeited by the Company in accordance herewith, (ii) sign on Grantee’s behalf any instrument required in order to effect a transfer of the Repurchased Shares, and/or (iii) execute and sign on Grantee’s behalf any instrument required in order to effect, any of other actions detailed in subsection 6(f)(ii) below. The Repurchased Shares shall be transferred to the Company or its designee free and clear of any lien, pledge, charge, security interest, encumbrance, restriction, option or other rights of any third party.

 

ii. Notwithstanding anything to the contrary in the Plan, the parties agree that in the event that the Company shall be prohibited, on account of any applicable law, from repurchasing Restricted Shares, the Company may (i) affect the forfeiture thereof for the benefit of the Company; (ii) designate a designee who shall conduct the repurchase and shall cooperate with the Company in order to hold the repurchased Restricted Shares in trust for future allocations of Ordinary Shares, issuable upon exercise of employee share options; (iii) transfer such repurchased Restricted Shares to all of the shareholders of the Company (other than the Grantee), on a pro-rata, as converted basis; (iv) make any other changes or amendments to the corporate documents of the Company in order to strip any Restricted Shares repurchased by the Company or its designee hereunder, of any rights or privileges they may have.

 

-9-

 

 

(g) The Company’s right of repurchase and/or forfeiture of Shares pursuant to this Section 6, shall not apply with respect to Shares which were issued to Grantees as a result of exercise of Options pursuant to the terms hereof, provided, however, that nothing contained herein shall derogate from the Company’s right to repurchase any Shares, in the event that Grantee’s engagement with the Company was terminated for Cause following such exercise of Options and/or issuance of Shares, in accordance with Section 12(c) below.

 

7. Term of Option

 

Without derogating from the rights and powers of the Board, each unexercised Option granted pursuant to the Plan shall expire upon the tenth (10th) anniversary of the Date of Grant thereof or, in the event of termination of Grantee’s employment or service with the Company or any of its Subsidiaries, as provided for in Section 12 below. It is hereby clarified that the Board may establish a shorter or longer term for an Option, as well as circumstances under which such Option shall be cancelled or expire.

 

8. Exercise Price and Consideration

 

(a) The Exercise Price shall be determined by the Board in its sole discretion.

 

(b) Each Grant Agreement will contain the Exercise Price determined for each Option covered thereby.

 

(c) The consideration to be paid for the Shares to be issued upon exercise of an Option, including the currency and the method of payment, shall be determined by the Board and, except in the case of a net exercise (as provided below), may consist entirely of (1) cash, (2) check, (3) wire transfer, or (3) any combination of the foregoing methods of payment.

 

(d) The proceeds received by the Company from the issuance of Shares and/or Shares subject to the Options will be added to the general funds of the Company and used at the Company’s discretion.

 

9. Vesting of the Options

 

(a) Unless otherwise determined by the Board with respect to any specific Optionee and/or Option and provided accordingly in the applicable Grant Agreement, the Option shall vest and become exercisable according to the following three (3) year vesting schedule such that one third (1/3) of the Options granted shall become vested upon lapse of each year as of the Date of Grant, or any other date determined by the Board, provided that on and before the respective preceding Vesting Dates Optionee shall be and shall have been continuously employed by the company to provided services to the Company.

 

(b) An Option may be subject to such other terms and conditions as to the time or times when it may be exercised, as well as the number of Shares which may be purchased under the Option (including by way of performance conditions), as the Board may deem appropriate. The vesting provisions of individual Options may vary.

 

(c) This Section shall apply, mutatis mutandis to issuance of Restricted Share.

 

-10-

 

 

10. Exercise of Option

 

(a) Options shall be exercised by the Optionee by giving written notice to the Company, in such form and method as may be determined by the Board and when applicable, by the Trustee in accordance with the requirements of Section 102 of the Tax Ordinance, which exercise shall be effective upon receipt of such notice by the Company together with full payment of the Exercise Price at the Company’s principal office and the execution and delivery of any other document required pursuant to the applicable Grant Agreement and Applicable Laws. The notice shall specify the number of Shares with respect to which the Option is being exercised. The notice of exercise is irrevocable and may not be rescinded or revised once it has been delivered to the Company; Optionee shall also send a copy of such notice of exercise to the Trustee.

 

(b) Each Option granted under the Plan shall be exercisable following the Vesting Dates and for the number of Shares as shall be provided in Exhibit B to the Grant Agreement. However, no Option shall be exercisable after the Expiration Date set forth in the Grant Agreement.

 

(c) Unless determined otherwise by the Board, the exercise of Options may be made through a “Net Exercise Mechanism” which shall operate as follows: the Optionee shall submit an exercise notice which shall include among others, the following particulars: (i) the number of the vested Options to be exercised and (ii) the aggregate Exercise Price of all of the Options to be exercised. Unless otherwise instructed by the Company, the benefit shall be calculated based on the difference between (i) the aggregate Exercise Price of all the Options being exercised; and (ii) the aggregate Fair Market Value of the Shares underlying such Options as of the date of such exercise notice received by the Company (the “Benefit”). The Company shall issue the Optionee or the Trustee, as applicable, with a number of whole Shares calculated by dividing the Benefit with the Fair Market Value of one Share as of the date of receipt of the exercise notice, as set forth in the Calculation Formula below (the “Net Exercise Mechanism”).

 

Calculation Formula:

 

A = the number of Options that the Optionee requests to exercise as specified in the exercise notice;

 

B = the Fair Market Value on the date of exercise;

 

C = the Exercise Price of each Option.

 

Number of Shares = A x ((B-C)/B)

 

The exercise of Options under this Section 10(b) and the amount of tax payable in respect of the sale of issued Shares shall be subject to the provision of a tax ruling of the Israeli Tax Authority received by the Company with respect to the Net Exercise Mechanism.

 

(d) The Options may be exercised by the Optionee in whole at any time or in part from time to time, to the extent that the Options become vested and exercisable, prior to the Expiration Date, and provided that, subject to the provisions of Section 12 below, the Optionee is employed by or providing services to the Company or any of its Affiliates, at all times during the period beginning with the Date of Grant and ending upon the date of exercise.

 

-11-

 

 

(e) An Option may not be exercised unless, at the time the Optionee gives the notice of exercise, the Optionee includes with such notice payment in cash or by bank check or by wire transfer of all withholding taxes due, if any, on account of the Shares being purchased under the Option or gives other assurance satisfactory to the Board and the Trustee of the payment of applicable withholding taxes. If the Company is not certain as to the sum of the applicable withholding tax, the Company may require that the Optionee present a valid exemption from withholding, issued by the relevant tax authority in favour of the Company.

 

(f) Shares shall not be issued pursuant to the exercise of an Option unless the exercise of such Option, the method of payment and the issuance and delivery of such Shares shall comply with Applicable Laws.

 

11. Right as a Shareholder

 

(a) Shares and Options issued pursuant to the Plan (including upon exercise of an Option) shall be issued in the name of the Grantee, except for (i) Approved 102 Shares; and/or (ii) Approved 102 Options; and/or (iii) Shares issued pursuant to the exercise of Approved 102 Options, all of which shall be issued to the Trustee in the name of the Grantee and held by the Trustee at least until the End of the Period (unless otherwise permitted by the applicable provisions of Section 102 and the regulations promulgated thereunder; it being understood that any release by the Trustee of the aforesaid Options or Shares may result in increased taxation), or for such longer period, as may be set forth in the Grant Agreement.

 

(b) With respect to Options, prior to exercise and until the registration of the Optionee as a holder of Shares in the Company’s register of shareholders, an Optionee, as such, shall have no right to vote or receive dividends or any other rights of or as a shareholder

 

(c) For the avoidance of doubt, an Optionee shall not have any of the rights or privileges of a shareholder in the Company in respect of any Shares purchasable upon the exercise of any Options, until the Optionee shall have exercised the Option, paid the Exercise Price and applicable tax thereof and have been registered as a holder of such Shares in the Company’s register of shareholders upon exercise of the Options in accordance with the provisions of the Plan. In case of Options and Shares held by the Trustee, the provisions of Section 15 below shall apply.

 

(d) If any law or regulation requires the Company to take any action with respect to the Shares specified in such notice of exercise before the issuance thereof, then the date of their issuance shall be extended for the period necessary to take such action.

 

12. Termination of Employment

 

(a) Unless the Board shall otherwise determine at or after the grant, in the event of termination of an Optionee’s employment with the Company or any of its Affiliates other than for Cause, Disability, retirement or death, all Options issued to that Optionee, which are vested and exercisable at the time of such termination, may, unless earlier terminated in accordance with the provisions of the Plan or the Grant Agreement, be exercised within 90 days following the date of such termination or such other period as may be specified in the Grant Agreement or determined by the Board but in any event, no later than the Expiration Date. If, on the date of termination, the Shares subject to the Option have not vested in their entirety, any Shares covered by the unvested portion of the Option shall expire and be of no further force and effect and shall become issuable to other participants under the Plan, at the Board’s sole discretion. To the extent the vested portion of the Option is not so exercised and fully paid for within the time specified herein, such unexercised vested portion of the Option shall expire and be of no further force and effect, and the Shares covered by such unexercised vested portion of the Option shall revert to the Plan. For the avoidance of doubt - in the event that in connection therewith, any Approved 102 Options are still held by the Trustee, the trust with respect thereto shall ipso facto expire and all of the Shares covered by the vested and unvested portion of such Approved 102 Options shall revert to the Plan and be subject to issuance if the Optionee did not exercise the Options within the above stated period. For the purposes of this section 12, termination of employment or engagement shall mean the date the termination notice was given by the Optionee or his/her employer (irrespective of the effective date of such termination), unless otherwise agreed to in writing.

 

-12-

 

 

(b) If the Optionee’s employment with the Company or an Affiliate thereof, or, if applicable, the rendering of services by the Optionee to the Company or an Affiliate thereof is terminated because of Optionee’s death, retirement or Disability, then Optionee’s Options may be exercised, only to the extent that such Options are vested and exercisable by Optionee on the termination date or as otherwise determined by the Board. Such Options, to the extent vested as of the termination date, must be exercised by Optionee (or Optionee’s legal representative or authorized assignee), if at all, within eighteen (18) months after the termination date in the event of death, or within twelve (12) months from the date of termination in the event of Disability, or any other period determined by the Board. If on the date of termination there are Options, which have not vested, the Shares covered by the unvested portion of the Options shall revert to the Plan unless determined otherwise under a Grant Agreement or by the Board. If the Option is not exercised within the time specified herein or other period determined by the Board, the Option shall terminate, and the Shares covered by such Option shall revert to the Plan. For the avoidance of doubt - in the event that in connection therewith any Approved 102 Options are still held by the Trustee, the trust with respect thereto shall ipso facto expire and all of the Shares covered by the vested and unvested portion of such unexercised Approved 102 Options shall revert to the Plan.

 

(c) In the event of termination of Optionee’s employment with the Company or its Affiliates for Cause, or if applicable, the termination of services rendered by the Optionee to the Company or its Affiliates for Cause (or if earlier, upon the Optionee’s receipt of notice of termination for Cause), all outstanding Options granted to such Optionee (whether vested or not) shall, to the extent not theretofore exercised, immediately expire and shall be of no further force and effect as of the date of such termination and shall revert to the Plan, unless otherwise determined by the Board.

 

(d) With respect to an Unapproved 102 Option, if the Optionee ceases to be employed by the Company or any Affiliate, the Optionee shall extend to the Company and/or its Affiliate security or guarantee for the payment of tax due at the time of sale of Shares, all in accordance with the provisions of Section 102.

 

13. Adjustments

 

Unless otherwise provided in the Grant Agreement, upon the occurrence of any of the following described events, Grantee’s rights to purchase Shares under the Plan shall be adjusted as hereafter provided:

 

(a) Changes in Capitalization. Subject to any required action by the Company, the number of issued 102 Shares, the number of Shares covered by each outstanding Option, the number of Shares which have been reserved for issuance under the Plan but as to which no Options have yet been issued or which have reverted to the Plan upon cancellation or expiration of an Option, as well as the Exercise Price per share of Shares covered by each such outstanding Option, shall be proportionately and equitably adjusted for any share split, reverse share split, bonus shares (shares dividend), combination or reclassification of the Shares, all only if such triggering event generally applies to all Shares and so as to maintain the proportionate number of Shares without changing the aggregate purchase price, provided, however, that (i) fractions of a Share will not be issued but will be rounded down to the nearest whole Share; (ii) that to the extent the Company does not have sufficient distributable profits or premium, that the Exercise Price of any Option may not be decreased to below the par value of the Shares; and (iii) no adjustment shall be made by reason of the distribution of subscription rights (rights offering) on outstanding stock. Such adjustment shall be made by the Board, whose determination in that respect shall be final, binding and conclusive. Upon happening of any of the foregoing, the class and aggregate number of Shares issuable pursuant to the Plan (as set forth in Section 5 hereof), in respect of which Options have not yet been exercised, shall be appropriately adjusted, all as will be determined by the Board whose determination shall be final. With respect to Approved 102 Shares and Approved 102 Options, all of the Shares resulting from the adjustments will also be deposited with the Trustee on the same terms and conditions as the original Options or Shares.

 

-13-

 

 

(b) Dissolution or Liquidation. In the event of a voluntary dissolution or liquidation of the Company while unexercised Options remain outstanding under the Plan, then the Board, in its own discretion, may determine that such outstanding Options may be exercised in full by the Grantees as of the effective date of any such liquidation or dissolution of the company without regard to the vesting provisions of Section __ of the Plan. In case the Board determined that the outstanding Options may be exercised, then all such outstanding Options may be exercised in full by the Grantees giving notice in writing to the Company of their intention to so exercise.

 

(c) Transaction

 

i. Notwithstanding anything to the contrary herein, all unvested Options and Restricted Shares shall fully vest immediately prior to the consummation of a Transaction, provided, howeverm that the Board shall determine whether such acceleration shall apply to Grantees who work less than one year with the Company at the time of consummation of the Transaction.

 

ii. In the event of a Transaction, each outstanding unexercised Option and Restricted Share may – with the consent of the Board and the Successor Company or its Affiliate (as applicable) – be assumed by the Successor Company or an Affiliate of the Successor Company, or may be replaced by a share option, or a share, as applicable, in, or right against, the Successor Company or an Affiliate of the Successor Company, and appropriate adjustments shall be made in the number of shares (and respectively, in the case of Options, the Exercise Price per Share) in order to reflect such an assumption or replacement, based on the Fair Market Value of the Shares and the Fair Market Value of the shares or other assets underlying the post-assumption or replacing options - all subject to the determination of the Board, which determination shall be in its sole discretion and final.

 

iii. In the event that the Successor Company does not assume or substitute the Options and/or the Restricted Shares, or in the event that the Board decides that the Options and/or Restricted Shares shall not be assumed or substituted, the Board may decide – at its sole discretion – that the vesting periods set forth in one, some or all of the Grant Agreements (in the case of one or some, as aforesaid, the decision as to which one or which ones shall be at the sole discretion of the Board) shall be fully or partially accelerated. If as a result of such acceleration an Option becomes vested and exercisable, the Board shall notify the Optionee in writing or electronically that the Option shall be fully exercisable for a period of fifteen (15) days from the date of such notice, and the Option shall terminate upon the expiration of such period if not exercised earlier by the Optionee; provided, however, that the Board may elect to apply the provisions of clause (vi) below to the accelerated Options, in lieu of providing notification as set forth above.

 

iv. For the purposes of this section, the Option and Restricted Share shall be considered assumed if, following a Transaction, the Optionee receives the right, under similar terms as the terms of the Option or Restricted Share, as applicable, to purchase (for the same purchase price, as appropriately adjusted), for each Share subject to the Option or Restricted Share immediately prior to the Transaction, the consideration (whether shares, cash, or other securities or property) received in the Transaction by holders of Shares of the same class for each Share held on the effective date of the Transaction (and if such holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration received in the Transaction is not solely ordinary shares of the Successor Company or its Affiliate, the Board may, with the consent of the Successor Company, provide for each Optionee to receive solely ordinary shares (or their equivalent) of the Successor Company or its Affiliate equal in Fair Market Value to the per share consideration received by holders of Shares in the Transaction; and provided further that the Board may determine, in its discretion that in lieu of such assumption or substitution of Options and Restricted shares for options and restricted shares of the Successor Company, or its Affiliate, such Options and Restricted Shares will be substituted for any other type of asset or property which is fair under the circumstances, including, without limitation, cash.

 

v. The issuance of 102 Shares or Options under the Plan shall in no way affect the right of the Company to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.

 

-14-

 

 

vi. Notwithstanding anything herein to the contrary, in connection with a Transaction, the Board – at its sole discretion – may determine that all Options and Restricted Shares which are “in the money” with respect to the Transaction, shall be replaced with the right of the Optionee to receive the difference between the per-share consideration being paid in the Transaction for each Share, and the Exercise Price, minus the amount of any applicable withholding taxes, and all Options and/or Restricted Shares which are not “in the money” may, at the full discretion of the Board, be cancelled or assumed as aforesaid. In addition, the Board may – at its sole discretion - decide that the Optionees shall be subject to all or some of the same terms and conditions, and risks (including, without limitation, escrows, liability for representations, uncertain contingent payments, and uncertain milestone payments), as the risks being taken by the Company’s shareholders in the Transaction, pro rata and mutatis mutandis, and each Optionee, by signing his Grant Agreement, agrees that the agreement covering the Transaction may contain provisions to that effect, without the need for the Optionee to execute, or otherwise consent to the provisions of, the agreement covering the Transaction.

 

14. Designation of Shares and/or Options Pursuant to Section 102

 

(a) The Board may designate Approved 102 Shares and/or Approved 102 Options as either CGO or OIO. The Company’s election of the type of Approved 102 Shares and/or Approved 102 Options to be issued to Employees (the “Election”) shall be appropriately filed with the Israeli Tax Authorities before the Date of Grant of any Approved 102 Share and/or Approved 102 Option.

 

(b) The Election of the type of Approved 102 Shares and/or Approved 102 Options to be issued to Employees, shall become effective beginning on the first Date of Grant of Approved 102 Shares and/or Approved 102 Options under the Plan and shall remain in effect until at least the end of the year following the year during which the Company first issued the Approved 102 Shares and/or Approved 102 Options under the Election. The Election shall obligate the Company to issue only the type of Approved 102 Shares and/or Approved 102 Options it has elected, and shall apply to all Approved 102 Shares and/or Approved 102 Options issued during the period indicated herein, all in accordance with the provisions of Section 102(g) of the Tax Ordinance. For the avoidance of doubt, such Election shall not prevent the Company from issuing Unapproved 102 Shares, Unapproved 102 Options or 3(i) Options, simultaneously or otherwise.

 

(c) No Approved 102 Shares and/or Approved 102 Options may be granted under this Plan, unless and until, the Plan shall be appropriately filed with the Israeli Tax Authorities at least thirty (30) days before the first Date of Grant.

 

(d) Each Grant Agreement shall state, inter alia, the type of Share and/or Option issued thereunder (whether a CGO, OIO, Unapproved 102 Shares, Unapproved 102 Option or a 3(i) Option), and if applicable, the vesting provisions and the Exercise Price.

 

(e) All Approved 102 Shares and/or Approved 102 Options must be held in trust by a Trustee, as described in Section 15 below.

 

(f) For the avoidance of doubt, the designation of 102 Shares and/or 102 Options shall be subject to the terms and conditions set forth in Section 102.

 

(g) With regard to Approved 102 Shares and/or Approved 102 Options, the provisions of the Plan and the Grant Agreement shall be subject to the provisions of Section 102 and the Tax Assessing Officer’s approval, and the said provisions and approval shall be deemed an integral part of the Plan and of the Grant Agreements. Any provision of Section 102 and/or the said approval which is necessary in order to receive and/or to keep any tax benefit pursuant to Section 102 of the Tax Ordinance, which is not expressly specified in the Plan or the Grant Agreement, shall be considered binding upon the Company and the Grantee. If any provision of the Plan should present any inconsistency or contradiction with Section 102, the provisions of Section 102 shall prevail.

 

-15-

 

 

15. Trustee

 

(a) Any Approved 102 Shares and/or Approved 102 Options shall be issued pursuant to the Plan to a Trustee. The Trustee shall hold such Approved 102 Shares and/or Approved 102 Options and any Shares issued upon the exercise of any of such Approved 102 Options, in trust pursuant to the Company’s instructions from time to time. The Company shall have the right to replace the Trustee with another trustee, which shall then become the Trustee under the Plan, subject to the approval of the Israeli Tax Authority, and without the need to receive the consent of the Grantees. The Trustee shall be entitled to make such provisions and take such steps as it may deem necessary or appropriate for the withholding of all taxes required by law to be withheld with respect to the Exercise of the Approved 102 Shares and/or Approved 102 Options. The Company shall deliver the Trustee all the necessary information required by it. The Trustee shall be exempt from any liability with respect to any action or decision duly taken in its capacity as Trustee, provided however that the Trustee has conducted its duties in good faith.

 

(b) Notwithstanding anything herein to the contrary, Approved 102 Shares and/or Approved 102 Options issued under the Plan, shall be issued to the Trustee and held for the benefit of the Grantee at least until the End of the Period, unless otherwise agreed by the Israeli Tax Authority or as may otherwise be permitted pursuant to Section 102 and the regulations promulgated thereunder. All Shares issued upon exercise of Approved 102 Options, all of the rights attached to and/or in connection with such Approved 102 Shares, Approved 102 Options and/or Shares issued upon exercise of Approved 102 Options, including without limitation dividend in shares, shall be issued to the Trustee and held by the Trustee for the benefit of the Grantee at least until the End of the Period and shall be subject to the same tax treatment as the treatment to which such Approved 102 Shares and/or Approved 102 Options are subject. In case the requirements pursuant to Section 102 for an Approved 102 Shares and/or Approved 102 Options are not met, then the Approved 102 Shares and/or Approved 102 Options may be regarded as Unapproved 102 Shares or Unapproved 102 Options, as applicable, all in accordance with the provisions of Section 102.

 

(c) Notwithstanding anything to the contrary, but subject to subsection (g) below, the Trustee shall not carry out any transaction or take any action with respect to Approved 102 Shares and/or Approved 102 Options or Shares issued upon exercise of the Options thereof, will not transfer, assign, release, pledge, mortgage voluntarily, or grant in connection therewith any proxy or assignment deed, whether immediately effective or effective at a future date, other than by will or by operation of law, until after the full payment of the Grantee’s tax liabilities arising from the issuance of such Approved 102 Shares and/or Approved 102 Options and their Exercise or after guarantying the payment of said taxes. If such Approved 102 Shares and/or Approved 102 Options or Shares pursuant to the exercise of such Options have been transferred by will or by operation of law, the provisions of Section 102 will apply with respect to the heirs or the transferees of the Grantee, as the case may be.

 

(d) Upon receipt of Approved 102 Shares and/or Approved 102 Options, the Grantee will sign an undertaking to release the Trustee from any liability in respect of any action or decision duly taken and bona fide executed in relation with the Plan, or any Approved 102 Shares and/or Approved 102 Options or Shares issued and held by Trustee pursuant thereto, released or transferred by the Trustee, in accordance with the provisions of Section 102.

 

-16-

 

 

(e) Except as otherwise permitted under the provisions of Section 102 and any ruling issued by the Israeli Tax Authority, until the End of the Period, a Grantee may not exercise Approved 102 Shares and/or CGO. At any time thereafter, each Grantee may require (but shall not be obligated to require) the Trustee to transfer to the Grantee, any Approved 102 Shares and/or Approved 102 Options or Shares issued pursuant to the exercise of such Approved 102 Options, provided that (1) such transfer is in compliance with all Applicable Laws, and (2) such Awards shall not be transferred to the Grantee before all applicable tax due pursuant to such an exercise has been paid in accordance with Section 102, and the Trustee has received an acknowledgement from the Israeli Tax Authority that the Grantee has paid any applicable tax due pursuant to Section 102. Notwithstanding the above, if any such sale or release occurs prior to the End of the Period, the sanctions under Section 102 shall apply to, and shall be borne by, such Grantee, except to the extent that the Israeli Tax Authority agrees otherwise.

 

(f) The Company shall not issue or grant Approved 102 Shares and/or Approved 102 Options to any Grantee unless the Grantee has given a statement in writing that he is familiar with the provisions of Section 102 and the type of Shares and/or Options issued to him, that he accepts the provisions of the Trust Agreement and that he undertakes not to exercise the Shares and/or Options before the End of the Period.

 

16. Dividends

 

With respect to all Shares (but excluding, for the avoidance of any doubt, any unexercised Options) issued, including, without limitation, upon the exercise of Options exercised by an Optionee, and held by the Grantee or by the Trustee, as the case may be, the Grantee (or the Trustee of his behalf, in the case of 102 Shares or Shares issued upon the exercise of 102 Options) shall be entitled to receive dividends in accordance with the quantity of such Shares, subject to the provisions of the Company’s Articles of Association (and all amendments thereto) and subject to any applicable taxation on distribution of dividends, and, when applicable, subject to the provisions of Section 102.

 

17. Restrictions on Assignability and Sale of Options/Shares; Power-of-Attorney

 

(a) No Option or any right with respect thereto, shall be assignable, transferable or given as collateral or any right with respect to it given to any third party whatsoever, except as specifically allowed under the Plan, and during the lifetime of the Optionee, each and all of such Optionee’s rights to purchase Shares hereunder shall be exercisable only by the Optionee. Any such action made directly or indirectly, for an immediate validation or for a future one, shall be void.

 

(b) So long as Options and/or Shares are held by the Trustee on behalf of the Optionee, all rights of the Optionee over the Shares are personal, cannot be transferred, assigned, pledged or mortgaged, other than by will or pursuant to the laws of descent and distribution.

 

(c) No Optionee shall have a right of first refusal or pre-emptive right in relation with any sale or issuance of shares in the Company, unless the Optionee is entitled to such right pursuant to the Articles of Association and subject and in accordance to the provisions thereof, as may be amended from time to time.

 

(d) Any Grantee to whom Shares are issued pursuant to the Plan, or for whom Shares are issued to the Trustee under the Plan, shall be entitled (in case the Shares are held by the Trustee – such entitlement shall be exercised by the Trustee) to all rights and privileges of holders of Shares, and shall be subject to (i) the provisions of the Company’s incorporation documents, as shall be amended from time to time, including, without limitation, right of first refusal/offer, preemptive rights, and “drag-along” provisions and right to receive notices for, and vote on, any meeting of the Company’s shareholder; (ii) any restrictions on transferability of shares pursuant to any instrument to which the Company is a party, including any shareholder agreements.

 

-17-

 

 

18. Amendment and Termination of the Plan

 

(a) Subject to Applicable Laws and Section 102, the Board may, at any time and from time to time, terminate, alter, adjust, suspend or amend the Plan, or any part thereof, in any respect, except that if at any time the approval of the shareholders of the Company is required pursuant to the Israeli Companies Law, 1999 or the regulations promulgated thereunder, the Board may not effect such modification or amendment without such approval.

 

(b) Termination of the Plan shall not affect the Board’s ability to exercise the powers granted to it hereunder with respect to Shares and/or Options issued under the Plan prior to the date of such termination, and the Plan shall continue to apply to those Shares and Options issued or granted prior to its termination (including Shares issued after the termination of the Plan but which were the subject of Options which were granted prior to the expiration of the Plan).

 

19. Integration of Section 102 And Tax Assessing Officer’s Approval

 

(a) With regard to 102 Shares and 102 Options, the provisions of the Plan and/or the Grant Agreement shall be subject to the provisions of Section 102 and the Tax Assessing Officer’s approval, and the said Section 102 and approval shall be deemed an integral part of the Plan and of the Grant Agreement.

 

(b) Any provision of Section 102 and/or the said approval which is necessary in order to receive and/or to keep any tax benefit pursuant to Section 102 of the Tax Ordinance, which is not expressly specified in the Plan or the Grant Agreement, shall be considered binding upon the Grantees, except as may be otherwise agreed by the Company.

 

20. General Provisions

 

(a) The Company and, if applicable, the Trustee, shall have the right to deduct from all amounts payable to a Grantee in cash (whether under this Plan or otherwise) any taxes required by law to be withheld in respect of Shares and/or Options under this Plan, or, at the Company’s discretion, demand as a condition to the sale of Shares or Option or the release of same by the Trustee, that the Grantee shall pay to the Company, in cash, or otherwise secure to the Company’s satisfaction, the tax amount required to be withheld.

 

(b) The Company may place a legend on each share certificate to the effect that such shares were acquired pursuant to an investment representation and are subject to limitations on offers, transfers and sales as the case may be.

 

(c) The Plan, the issuance and exercise of Shares and/or Options thereunder, and the other obligations of the Company under the Plan, shall be subject to all Applicable Laws, rules and regulations, and to such approvals by any regulatory or governmental agency as may be required. To the extent required in order to comply with Applicable Laws, the Company, in its discretion, may postpone any issuance and any exercise of Shares and/or Options, or any other action permitted under the Plan. The Company may be permitted, with reasonable diligence, to complete such stock exchange, or similar listing, registration, qualification of such Shares or other required action under any Applicable Laws, rules, or regulations. The Company may require any Grantee to make such representations and furnish such information, as it may consider appropriate in connection with the issuance or delivery of Shares in compliance with Applicable Laws, rules, and regulations. The Company shall not be obligated, by virtue of any provision of the Plan, to recognize the exercise of any Option or to otherwise sell or issue Shares in violation of any such Applicable Laws, rules, or regulations.

 

-18-

 

 

(d) Notwithstanding any other provision in this Plan, the Company will have no obligation to issue or deliver certificates for Shares under this Plan prior to (i) obtaining any approvals from governmental agencies that the Company determines are necessary or advisable, and/or (ii) compliance with any exemption, completion of any registration or other qualification of such Shares under any applicable laws or ruling of any governmental body that the Company determines to be necessary. The Company will be under no obligation to register the Shares with the Securities and Exchange Commission or to effect compliance with the exemption, registration, qualification or listing requirements of any state Securities Laws, stock exchange or automated quotation system, and the Company will have no liability for any inability or failure to do so.

 

(e) Except when otherwise indicated by the context, words in the masculine gender used in the Plan shall include the feminine gender, the singular shall include the plural, and the plural shall include the singular.

 

(f) The validity, construction, interpretation, administration and effect of the Plan and any rules, regulations and actions relating to the Plan will be governed by and construed exclusively in accordance with the laws of the State of Israel, notwithstanding the conflicts of laws principles of any jurisdiction. The competent courts in Tel Aviv shall have sole and exclusive jurisdiction over any dispute with regard to any controversy or claim arising under, out of, or in connection with this Plan, its validity, its interpretation, its execution or any breach or claimed breach thereof.

 

(g) In connection with any underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under Securities Laws, the Grantee undertakes that he/she shall not, directly or indirectly, sell, make any short sale of, loan, hypothecate, pledge, offer, grant or sell any Optionor Share or enter into any other contract for the purchase thereof, purchase any Option or Share or enter into any other contract for the sale thereof, or otherwise dispose of or transfer, or agree to engage in any of the foregoing transactions with respect to any Shares acquired under a Grant Agreement without the prior written consent of the Company or its underwriters. Such restriction (the “Market Stand-Off”) shall be in effect for such period of time following the date of the final prospectus for the offering as may be requested by the Company or such underwriters. In the event of the declaration of a stock dividend, a spin-off, a stock split, an adjustment in conversion ratio, a recapitalization or any similar transaction affecting the Company’s outstanding securities without receipt of consideration, in accordance with the provisions of this Plan, any new, substituted or additional securities which are by reason of such transaction distributed with respect to any Shares subject to the Market Stand-Off, or into which such Shares thereby become convertible, shall immediately be subject to the Market Stand-Off. In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions until the end of the applicable stand-off period. The Company’s underwriters shall be beneficiaries of the agreement set forth in this Section. This Section shall not apply to Shares registered in the public offering under the Securities Laws.

 

-19-

 

 

21. Date of Grant

 

Subject to Applicable Laws, the “Date of Grant” of an Option shall, for all purposes, be the date on which the Board makes the determination to grant such Option, as applicable, or such other date determined by the Board, subject to any other determination of the Israeli Tax Authority; provided that an Option shall expire automatically if the Grant Agreement relating thereto is not executed by the Grantee within 90 days thereafter.

 

22. Tax Consequences

 

(a) Any tax consequences and/or obligations and/or other compulsory payments arising from the issuance of Shares and/or issuance or exercise of any Option, from the payment for or from the disposition of Shares covered thereby or from any other event or act (whether of the Grantee, of the Company, of any Affiliates or of the Trustee) hereunder, shall be borne solely by the Grantee. The Company and/or the Trustee shall withhold taxes according to the requirements under the Tax Ordinance and/or the Applicable Laws, rules, and regulations. Furthermore, each Grantee shall indemnify the Company and any Affiliate that employs or engages the Grantee and/or the Trustee, and/or the Company’s and/or any Affiliate’s shareholders and/or directors and/or office holders (“Indemnified Party”), and hold them harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax (and compulsory payment, if any) from any payment made to the Grantee, provided however that the Indemnified Party has conducted his duties in good faith. Except as otherwise required by law, the Company shall not be obligated to honour the exercise of any Option by or on behalf of an Optionee or the disposition of any Share by a Grantee until all tax consequences (if any) arising from the exercise of such Options are resolved in a manner reasonably acceptable to the Company.

 

(b) The receipt of an Award and/or the acquisition of Shares issued upon the exercise of the Awards may result in tax consequences. The description of tax consequences set forth in the Plan or any Appendix hereto does not purport to be complete, up-to-date or to take into account any special circumstances relating to a Grantee.

 

(c) GRANTEES ARE ADVISED TO CONSULT WITH A TAX ADVISOR WITH RESPECT TO THE TAX CONSEQUENCES OF RECEIVING ANY AWARD IN LIGHT OF HIS PARTICULAR CIRCUMSTANCES.

 

23. Overseas Grantees

 

Notwithstanding any other provision of this Plan, but subject to Applicable Laws and Section 102 when applicable, the Board may, in respect of Shares and/or Options granted to Grantees who are or may become subject to taxation outside Israel on their remuneration and/or are Employees of or provide services to an Affiliate outside of Israel, amend or alter the provisions of this Plan as the Board considers necessary or desirable to mitigate, take account of or comply with relevant overseas taxation, securities, exchange control or other applicable laws. Any such amendment or alteration may be carried out by way of the adoption of one or more appendixes to the Plan.

 

-20-

 

 

24. Data Privacy

 

Grantee, by signing the Grant Agreement, explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of Grantee’s personal data as described in this Grant Agreement and any other Option grant materials by and among, as applicable, the Company and its Affiliates for the purpose of implementing, administering and managing Grantee’s participation in this Plan. Grantee understands that Grantee is not obligated under law to provide any information or consent to the collection, use and transfer of any Data (as defined below). However, without such consent participation in this Plan may not be possible. Grantee understands that the Company may hold, collect and produce certain personal information about Grantee, including, but not limited to, Grantee’s name, home address and telephone number, date of birth, identification number, salary, nationality, job title, any shares or directorships held in the Company, details of all Options or any other entitlement to Shares awarded, cancelled, exercised, vested, unvested or outstanding in Grantee’s favour, for the purpose of implementing, administering and managing this Plan (“Data”). Grantee understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of this Plan, as well as to prospective acquirers of the Company or investors therein for due diligence purposes. Grantee understands that the recipients of the Data may be located in Israel or elsewhere, and that the recipient’s country may have different data privacy laws and protections than Grantee’s country. Grantee hereby authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, including further transfers, for the purpose of implementing, administering and managing Grantee’s participation in this Plan, including any transfer of such Data as may be necessary or appropriate to a broker, escrow agent or other third party with whom the Issued Shares may be deposited.

 

25. Non-Exclusivity of the Plan

 

The adoption of the Plan by the Board shall not be construed as creating any limitations on the power of the Board to adopt such other incentive arrangements as it may deem desirable, including, without limitation, the issuing of Shares and/or Options otherwise than under the Plan, and such arrangements may be either applicable generally or only in specific cases.

 

26. Inability to Obtain Authority

 

The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary for the lawful issuance of any Shares hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained.

 

27. Multiple Agreements

 

The terms of each Grant Agreement may differ for each Grantee under the Plan at the same time or at any other time. The Board may also make more than one issuance of Shares and/or Options to a given Grantee during the term of the Plan, either in addition to, or in substitution for, one or more previous issuances to that Grantee.

 

******

 

 

-21-

 

 

Exhibit 31.1

 

CERTIFICATION

 

I, Yehuda Holtzman, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of On Track Innovations Ltd.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f)) of the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 16, 2021
    /s/ Yehuda Holtzman
    Yehuda Holtzman
    Chief Executive Officer
    (Principal Executive Officer)

Exhibit 31.2

 

CERTIFICATION

 

I, Assaf Cohen, certify that: 

 

1. I have reviewed this quarterly report on Form 10-Q of On Track Innovations Ltd.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f)) of the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 16, 2021     
  /s/ Assaf Cohen
    Assaf Cohen
    Chief Financial Officer
    (Principal Financial Officer)

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

  

In connection with the Quarterly Report of On Track Innovations Ltd. (the “Company”) on Form 10-Q for the period ended June 30, 2021 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Yehuda Holtzman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 16, 2021
    By: /s/ Yehuda Holtzman
    Yehuda Holtzman
    Chief Executive Officer

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

  

In connection with the Quarterly Report of On Track Innovations Ltd. (the “Company”) on Form 10-Q for the period ended June 30, 2021 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Assaf Cohen, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 16, 2021  
  By: /s/ Assaf Cohen
 

Assaf Cohen

Chief Financial Officer